<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>NVIDIA Corporation (NASDAQ:NVDA) TD Cowen 45th Annual Health Care Conference March 3, 2025 11:10 AM ET<br><br>Company Participants<br><br>Kimberly Powell â€“ Vice President, Healthcare, NVIDIA<br><br>Conference Call Participants<br><br>Josh Buchalter â€“ TD Cowen<br>Brendan Smith â€“ TD Cowen<br><br>Josh Buchalter<br><br>All right. Good morning everybody. Thank you for joining us at our Healthcare Conference. I'm Josh Buchalter, Semiconductor Analyst at TD Cowen. Really pleased to be joined by my colleague Brendan Smith, who covers life science tools and diagnostics and biotechnology, to host a discussion with Kimberly Powell, VP of Healthcare at NVIDIA.</td><td>NVIDIA Corporation (NASDAQ:NVDA) TD Cowen ì œ45íšŒ ì—°ë¡€ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ 2025ë…„ 3ì›” 3ì¼ ì˜¤ì „ 11ì‹œ 10ë¶„ ET<br><br>ì°¸ì„ì<br><br>Kimberly Powell â€“ NVIDIA í—¬ìŠ¤ì¼€ì–´ ë¶€ë¬¸ ë¶€ì‚¬ì¥<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>Josh Buchalter â€“ TD Cowen<br>Brendan Smith â€“ TD Cowen<br><br>Josh Buchalter<br><br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤, ì—¬ëŸ¬ë¶„. ì €í¬ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì €ëŠ” TD Cowenì˜ ë°˜ë„ì²´ ì• ë„ë¦¬ìŠ¤íŠ¸ Josh Buchalterì…ë‹ˆë‹¤. ìƒëª…ê³¼í•™ ë„êµ¬ ë° ì§„ë‹¨, ìƒëª…ê³µí•™ ë¶„ì•¼ë¥¼ ë‹´ë‹¹í•˜ëŠ” ë™ë£Œ Brendan Smithì™€ í•¨ê»˜ NVIDIA í—¬ìŠ¤ì¼€ì–´ ë¶€ë¬¸ ë¶€ì‚¬ì¥ Kimberly Powellê³¼ì˜ í† ë¡ ì„ ì§„í–‰í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤.</td></tr>
<tr><td>Brendan, thanks for inviting me to your party; and Kimberly, thank you for joining us. Kimberly Powell<br><br>Thank you for having. Brendan Smith<br><br>Thank you. Josh Buchalter<br><br>I guess to start, maybe get the elephant out of the room, what's a semiconductor company doing at a healthcare conference? From a high level, how does NVIDIA support the healthcare market and how does it fit into the broader NVIDIA story? Kimberly Powell<br><br>Yes. So let me take one minute to. As a reminder, this presentation contains forward-looking statements and investors are advised to read our reports filed with the SEC for information related to risks and uncertainties facing the business. But I appreciate the question.</td><td>ë¸Œë Œë“ , íŒŒí‹°ì— ì´ˆëŒ€í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  í‚´ë²Œë¦¬, í•¨ê»˜í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. í‚´ë²Œë¦¬ íŒŒì›”<br><br>ì°¸ì„í•˜ê²Œ í•´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ë¸Œë Œë“  ìŠ¤ë¯¸ìŠ¤<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ì¡°ì‹œ ë¶€ì°°í„°<br><br>ì‹œì‘í•˜ê¸°ì— ì•ì„œ, ì•„ë§ˆë„ í•µì‹¬ ì´ìŠˆë¶€í„° ë‹¤ë¤„ë³´ê² ìŠµë‹ˆë‹¤. ë°˜ë„ì²´ íšŒì‚¬ê°€ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ë¬´ì—‡ì„ í•˜ê³  ìˆëŠ” ê±´ê°€ìš”? ë†’ì€ ìˆ˜ì¤€ì—ì„œ ë³´ë©´, NVIDIAëŠ” í—¬ìŠ¤ì¼€ì–´ ì‹œì¥ì„ ì–´ë–»ê²Œ ì§€ì›í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ë” ë„“ì€ NVIDIA ìŠ¤í† ë¦¬ì— ì–´ë–»ê²Œ ë¶€í•©í•˜ëŠ”ì§€ìš”? í‚´ë²Œë¦¬ íŒŒì›”<br><br>ë„¤. ê·¸ëŸ¼ ì ì‹œ ì‹œê°„ì„ ë‚´ì–´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ, ì´ í”„ë ˆì  í…Œì´ì…˜ì—ëŠ” ë¯¸ë˜ ì „ë§ ì§„ìˆ ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, íˆ¬ììë“¤ê»˜ì„œëŠ” ì‚¬ì—…ì´ ì§ë©´í•œ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì— ê´€í•œ ì •ë³´ë¥¼ ìœ„í•´ SECì— ì œì¶œí•œ ì €í¬ ë³´ê³ ì„œë¥¼ ì½ì–´ë³´ì‹œê¸° ë°”ëë‹ˆë‹¤. í•˜ì§€ë§Œ ì§ˆë¬¸í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Let's take a step back. For about two decades now, NVIDIA has dedicated themselves to what's called accelerated computing. Accelerated computing was originally adopted by the medical community, some of the earliest applications in fact came from the medical community, medical imaging, molecular dynamics simulation, genomics analysis. So what have we done here? NVIDIA has, we build computers that solve problems no other computers can. And these are led us to some of the most important breakthroughs that we're living through right now. One of those breakthroughs, of course, is artificial intelligence.</td><td>í•œ ê±¸ìŒ ë¬¼ëŸ¬ì„œì„œ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ì§€ë‚œ ì•½ 20ë…„ê°„ NVIDIAëŠ” ê°€ì† ì»´í“¨íŒ…(accelerated computing)ì´ë¼ê³  ë¶ˆë¦¬ëŠ” ë¶„ì•¼ì— ì „ë…í•´ì™”ìŠµë‹ˆë‹¤. ê°€ì† ì»´í“¨íŒ…ì€ ì²˜ìŒì—ëŠ” ì˜ë£Œê³„ì—ì„œ ì±„íƒë˜ì—ˆìœ¼ë©°, ì‹¤ì œë¡œ ê°€ì¥ ì´ˆê¸°ì˜ ì‘ìš© ë¶„ì•¼ë“¤ì´ ì˜ë£Œê³„ì—ì„œ ë‚˜ì™”ìŠµë‹ˆë‹¤. ì˜ë£Œ ì˜ìƒ, ë¶„ì ë™ì—­í•™ ì‹œë®¬ë ˆì´ì…˜, ìœ ì „ì²´í•™ ë¶„ì„ ë“±ì´ ê·¸ê²ƒì…ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ìš°ë¦¬ê°€ ì—¬ê¸°ì„œ ë¬´ì—‡ì„ í•´ì™”ì„ê¹Œìš”? NVIDIAëŠ” ë‹¤ë¥¸ ì–´ë–¤ ì»´í“¨í„°ë„ í•´ê²°í•  ìˆ˜ ì—†ëŠ” ë¬¸ì œë“¤ì„ í•´ê²°í•˜ëŠ” ì»´í“¨í„°ë¥¼ êµ¬ì¶•í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ìš°ë¦¬ê°€ ì§€ê¸ˆ ê²½í—˜í•˜ê³  ìˆëŠ” ê°€ì¥ ì¤‘ìš”í•œ í˜ì‹ ë“¤ë¡œ ì´ì–´ì¡ŒìŠµë‹ˆë‹¤. ë¬¼ë¡  ê·¸ëŸ¬í•œ í˜ì‹  ì¤‘ í•˜ë‚˜ê°€ ë°”ë¡œ ì¸ê³µì§€ëŠ¥ì…ë‹ˆë‹¤.</td></tr>
<tr><td>But many other areas of science are also having incredible breakthroughs, whether that's climate science, now drug discovery and you're, of course, hearing a lot more of the increase in what's going to transpire in physical AI and robotics. And so NVIDIA is not a semiconductor company any longer. We build what's called full stack data center solutions where there is a GPU, of course, graphics processing unit, but it's accompanied with CPUs that we also design networking, full data center scale technologies that really allow for us to make computing go through what is unimaginable in the previous generations of computing.</td><td>í•˜ì§€ë§Œ ê³¼í•™ì˜ ë‹¤ë¥¸ ë§ì€ ë¶„ì•¼ì—ì„œë„ ë†€ë¼ìš´ ëŒíŒŒêµ¬ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ê¸°í›„ ê³¼í•™ì´ë“ , í˜„ì¬ì˜ ì‹ ì•½ ê°œë°œì´ë“ , ê·¸ë¦¬ê³  ë¬¼ë¡  ì—¬ëŸ¬ë¶„ë„ ë¬¼ë¦¬ì  AIì™€ ë¡œë³´í‹±ìŠ¤ ë¶„ì•¼ì—ì„œ ì•ìœ¼ë¡œ ì¼ì–´ë‚  ë°œì „ì— ëŒ€í•´ í›¨ì”¬ ë” ë§ì´ ë“£ê³  ê³„ì‹¤ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ NVIDIAëŠ” ë” ì´ìƒ ë°˜ë„ì²´ íšŒì‚¬ê°€ ì•„ë‹™ë‹ˆë‹¤. ì €í¬ëŠ” í’€ìŠ¤íƒ ë°ì´í„°ì„¼í„° ì†”ë£¨ì…˜ì´ë¼ê³  ë¶ˆë¦¬ëŠ” ê²ƒì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¬¼ë¡  GPU, ì¦‰ ê·¸ë˜í”½ ì²˜ë¦¬ ì¥ì¹˜ê°€ ìˆì§€ë§Œ, ì €í¬ê°€ ì„¤ê³„í•˜ëŠ” CPUì™€ ë„¤íŠ¸ì›Œí‚¹, ê·¸ë¦¬ê³  ë°ì´í„°ì„¼í„° ì „ì²´ ê·œëª¨ì˜ ê¸°ìˆ ë“¤ì´ í•¨ê»˜ ë™ë°˜ë˜ì–´, ì´ì „ ì„¸ëŒ€ì˜ ì»´í“¨íŒ…ì—ì„œëŠ” ìƒìƒí•  ìˆ˜ ì—†ì—ˆë˜ ì»´í“¨íŒ…ì„ ì‹¤í˜„í•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>For example, 1 million times of compute performance has been achieved in the last 10 years. This is orders and orders of magnitude more computational capabilities than the previous Mooreâ€™s Law of computing had brought us. And so here we are, we have invented our latest architecture, which is called Blackwell. Blackwell has been built for the modern AI of agents that we are now living in. There are new laws of scaling that you're all, I'm sure, starting to learn quickly about. The first law of scaling is now what's called pre-training, pre-training the LLMs. This is like sending your child to grade school, all the way up through high school.</td><td>ì˜ˆë¥¼ ë“¤ì–´, ì§€ë‚œ 10ë…„ ë™ì•ˆ 100ë§Œ ë°°ì˜ ì»´í“¨íŒ… ì„±ëŠ¥ í–¥ìƒì´ ë‹¬ì„±ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê¸°ì¡´ ë¬´ì–´ì˜ ë²•ì¹™ì´ ê°€ì ¸ë‹¤ì¤€ ê²ƒë³´ë‹¤ ëª‡ ì°¨ì› ë” ë†’ì€ ìˆ˜ì¤€ì˜ ì»´í“¨íŒ… ì—­ëŸ‰ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ê¸ˆ ìš°ë¦¬ëŠ” ë¸”ë™ì›°(Blackwell)ì´ë¼ê³  ë¶ˆë¦¬ëŠ” ìµœì‹  ì•„í‚¤í…ì²˜ë¥¼ ë°œëª…í–ˆìŠµë‹ˆë‹¤. ë¸”ë™ì›°ì€ ìš°ë¦¬ê°€ í˜„ì¬ ì‚´ê³  ìˆëŠ” ì—ì´ì „íŠ¸ì˜ í˜„ëŒ€ì  AIë¥¼ ìœ„í•´ êµ¬ì¶•ë˜ì—ˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ ëª¨ë‘ê°€ ë¹ ë¥´ê²Œ ë°°ìš°ê¸° ì‹œì‘í•˜ê³  ìˆì„ ìƒˆë¡œìš´ ìŠ¤ì¼€ì¼ë§ ë²•ì¹™ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ ìŠ¤ì¼€ì¼ë§ ë²•ì¹™ì€ ì´ì œ ì‚¬ì „ í›ˆë ¨(pre-training), ì¦‰ LLMì˜ ì‚¬ì „ í›ˆë ¨ì´ë¼ê³  ë¶ˆë¦½ë‹ˆë‹¤. ì´ëŠ” ë§ˆì¹˜ ìë…€ë¥¼ ì´ˆë“±í•™êµë¶€í„° ê³ ë“±í•™êµê¹Œì§€ ë³´ë‚´ëŠ” ê²ƒê³¼ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It's the foundation at which they build the ability to learn, memorizing facts about history or other kind of fields of science. So pre-training requires a lot of data, a lot of infrastructure to create a model. There is a second law which is called post-training. This is a bit like getting a post-doc. This is where you're now fine tuning the skills with more domain specific information or task specific information so that you can have these AI models do jobs with the utmost accuracy. And then there is a third scaling law which we're living through, which is called test-time compute. And this is actually where AI goes off and it thinks. You've all heard about what's called reasoning models.</td><td>ì´ëŠ” í•™ìŠµ ëŠ¥ë ¥ì„ êµ¬ì¶•í•˜ëŠ” ê¸°ë°˜ì´ ë˜ë©°, ì—­ì‚¬ë‚˜ ê¸°íƒ€ ê³¼í•™ ë¶„ì•¼ì˜ ì‚¬ì‹¤ë“¤ì„ ì•”ê¸°í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì‚¬ì „ í›ˆë ¨ì—ëŠ” ëª¨ë¸ì„ ë§Œë“¤ê¸° ìœ„í•´ ëŒ€ëŸ‰ì˜ ë°ì´í„°ì™€ ë§ì€ ì¸í”„ë¼ê°€ í•„ìš”í•©ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ë²•ì¹™ì€ ì‚¬í›„ í›ˆë ¨ì´ë¼ê³  ë¶ˆë¦½ë‹ˆë‹¤. ì´ëŠ” ë°•ì‚¬í›„ ê³¼ì •ì„ ë°›ëŠ” ê²ƒê³¼ ë¹„ìŠ·í•©ë‹ˆë‹¤. ì—¬ê¸°ì„œëŠ” ë” ë„ë©”ì¸ë³„ ì •ë³´ë‚˜ ì‘ì—…ë³„ ì •ë³´ë¡œ ê¸°ìˆ ì„ ë¯¸ì„¸ ì¡°ì •í•˜ì—¬ ì´ëŸ¬í•œ AI ëª¨ë¸ë“¤ì´ ìµœê³ ì˜ ì •í™•ë„ë¡œ ì—…ë¬´ë¥¼ ìˆ˜í–‰í•  ìˆ˜ ìˆë„ë¡ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ í˜„ì¬ ê²½í—˜í•˜ê³  ìˆëŠ” ì„¸ ë²ˆì§¸ ìŠ¤ì¼€ì¼ë§ ë²•ì¹™ì´ ìˆëŠ”ë°, ì´ë¥¼ í…ŒìŠ¤íŠ¸ íƒ€ì„ ì»´í“¨íŠ¸ë¼ê³  í•©ë‹ˆë‹¤. ì´ëŠ” ì‹¤ì œë¡œ AIê°€ ë‚˜ê°€ì„œ ì‚¬ê³ í•˜ëŠ” ë‹¨ê³„ì…ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ ëª¨ë‘ ì¶”ë¡  ëª¨ë¸ì´ë¼ê³  ë¶ˆë¦¬ëŠ” ê²ƒì— ëŒ€í•´ ë“¤ì–´ë³´ì…¨ì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And so we've built the Blackwell architecture to advance these incredible three new scaling laws and really unlock the world that we're living in now, which is agentic AI and then I'll talk to you a little bit more about the very near future here that we're inventing, which is physical AI. And so all that we're building here in terms of the computing platform has huge applicability into healthcare and I know we're going to talk more about those applications. Josh Buchalter<br><br>For sure. Now thank you for that, Kimberly, and I definitely want to get back to the scaling laws.</td><td>ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì´ ë†€ë¼ìš´ ì„¸ ê°€ì§€ ìƒˆë¡œìš´ ìŠ¤ì¼€ì¼ë§ ë²•ì¹™ì„ ë°œì „ì‹œí‚¤ê³  í˜„ì¬ ìš°ë¦¬ê°€ ì‚´ê³  ìˆëŠ” ì„¸ê³„, ì¦‰ ì—ì´ì „í‹± AIì˜ ì„¸ê³„ë¥¼ ì§„ì •ìœ¼ë¡œ ì—´ì–´ì£¼ê¸° ìœ„í•´ Blackwell ì•„í‚¤í…ì²˜ë¥¼ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ë°œëª…í•˜ê³  ìˆëŠ” ì•„ì£¼ ê°€ê¹Œìš´ ë¯¸ë˜ì¸ ë¬¼ë¦¬ì  AIì— ëŒ€í•´ì„œë„ ì¡°ê¸ˆ ë” ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ê°€ ì»´í“¨íŒ… í”Œë«í¼ ì¸¡ë©´ì—ì„œ êµ¬ì¶•í•˜ê³  ìˆëŠ” ëª¨ë“  ê²ƒì€ í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ì— ì—„ì²­ë‚œ ì ìš© ê°€ëŠ¥ì„±ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì‘ìš© ë¶„ì•¼ì— ëŒ€í•´ ë” ìì„¸íˆ ë…¼ì˜í•  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. <br><br>Josh Buchalter<br><br>ë¬¼ë¡ ì…ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤, Kimberly. ê·¸ë¦¬ê³  ì €ëŠ” í™•ì‹¤íˆ ìŠ¤ì¼€ì¼ë§ ë²•ì¹™ìœ¼ë¡œ ë‹¤ì‹œ ëŒì•„ê°€ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But maybe to start, I think you've described healthcare as potentially the largest opportunity within your AI ecosystem and I think you've described three main buckets: digital surgery, digital biology and digital health. Could you maybe speak to the maturity of those three verticals, where they are today and the potential size of them long-term within NVIDIA's model? And then I'll turn it over to Brendan. Kimberly Powell<br><br>Yes, absolutely. So we all know that healthcare is about a $10 trillion industry globally. And in fact of that $10 trillion, upwards of 30% of that is in the form of labor, labs and infrastructure, physical infrastructure in order to deliver healthcare.</td><td>í•˜ì§€ë§Œ ë¨¼ì € ì‹œì‘í•˜ê¸° ì „ì—, ê·€í•˜ê»˜ì„œ í—¬ìŠ¤ì¼€ì–´ë¥¼ AI ìƒíƒœê³„ ë‚´ì—ì„œ ì ì¬ì ìœ¼ë¡œ ê°€ì¥ í° ê¸°íšŒë¡œ ì„¤ëª…í•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìœ¼ë©°, ì„¸ ê°€ì§€ ì£¼ìš” ì˜ì—­ìœ¼ë¡œ ë””ì§€í„¸ ìˆ˜ìˆ , ë””ì§€í„¸ ìƒë¬¼í•™, ê·¸ë¦¬ê³  ë””ì§€í„¸ í—¬ìŠ¤ë¥¼ ì–¸ê¸‰í•˜ì…¨ìŠµë‹ˆë‹¤. ì´ ì„¸ ê°€ì§€ ìˆ˜ì§ ì˜ì—­ì˜ ì„±ìˆ™ë„, í˜„ì¬ ìƒí™©, ê·¸ë¦¬ê³  NVIDIA ëª¨ë¸ ë‚´ì—ì„œì˜ ì¥ê¸°ì ì¸ ì ì¬ ê·œëª¨ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ í›„ì— ë¸Œë Œë˜ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>**í‚´ë²Œë¦¬ íŒŒì›”**<br><br>ë„¤, ë¬¼ë¡ ì…ë‹ˆë‹¤. ìš°ë¦¬ ëª¨ë‘ ì•Œê³  ìˆë“¯ì´ í—¬ìŠ¤ì¼€ì–´ëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ ì•½ 10ì¡° ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‚°ì—…ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ ì´ 10ì¡° ë‹¬ëŸ¬ ì¤‘ì—ì„œ 30% ì´ìƒì´ í—¬ìŠ¤ì¼€ì–´ë¥¼ ì œê³µí•˜ê¸° ìœ„í•œ ì¸ë ¥, ì‹¤í—˜ì‹¤, ê·¸ë¦¬ê³  ë¬¼ë¦¬ì  ì¸í”„ë¼ í˜•íƒœë¡œ êµ¬ì„±ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I think we can all recognize that even here where we live in very well endowed country, we're still at a drastic supply and demand shortage, demand of healthcare services and the supply of healthcare services, we're at an extreme shortage, tens of millions of humans short, which is equal to trillions of dollars each. 10 million people in the healthcare services is approximately a trillion dollars. And so AI has to help. It's a bit existential in that way. AI has to help. And so, we think about it in really three major buckets as you described. One area and this is the area that we've been in the longest, is really in the area of digital devices, right.</td><td>ì €í¬ê°€ ëª¨ë‘ ì¸ì‹í•  ìˆ˜ ìˆëŠ” ê²ƒì€, ë§¤ìš° í’ìš”ë¡œìš´ êµ­ê°€ì— ì‚´ê³  ìˆëŠ” ì´ê³³ì—ì„œì¡°ì°¨ ì—¬ì „íˆ ì˜ë£Œ ì„œë¹„ìŠ¤ì˜ ê³µê¸‰ê³¼ ìˆ˜ìš” ê°„ì— ê·¹ì‹¬í•œ ë¶€ì¡± í˜„ìƒì´ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì˜ë£Œ ì„œë¹„ìŠ¤ì— ëŒ€í•œ ìˆ˜ìš”ì™€ ì˜ë£Œ ì„œë¹„ìŠ¤ì˜ ê³µê¸‰ ì‚¬ì´ì— ê·¹ë‹¨ì ì¸ ë¶€ì¡± ìƒí™©ì— ìˆìœ¼ë©°, ìˆ˜ì²œë§Œ ëª…ì˜ ì¸ë ¥ì´ ë¶€ì¡±í•œ ìƒí™©ì…ë‹ˆë‹¤. ì´ëŠ” ê°ê° ìˆ˜ì¡° ë‹¬ëŸ¬ì— í•´ë‹¹í•˜ëŠ” ê·œëª¨ì…ë‹ˆë‹¤. ì˜ë£Œ ì„œë¹„ìŠ¤ ë¶„ì•¼ì˜ ì²œë§Œ ëª…ì€ ëŒ€ëµ 1ì¡° ë‹¬ëŸ¬ì— í•´ë‹¹í•©ë‹ˆë‹¤. ë”°ë¼ì„œ AIê°€ ë„ì›€ì„ ì£¼ì–´ì•¼ í•©ë‹ˆë‹¤. ì–´ë–¤ ë©´ì—ì„œëŠ” ì‹¤ì¡´ì ì¸ ë¬¸ì œë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. AIê°€ ë°˜ë“œì‹œ ë„ì›€ì„ ì£¼ì–´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ë§ì”€í•˜ì‹  ëŒ€ë¡œ í¬ê²Œ ì„¸ ê°€ì§€ ì£¼ìš” ì˜ì—­ìœ¼ë¡œ ë‚˜ëˆ„ì–´ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•œ ì˜ì—­ì€ ì €í¬ê°€ ê°€ì¥ ì˜¤ë«ë™ì•ˆ ì°¸ì—¬í•´ì˜¨ ë¶„ì•¼ì¸ë°, ë°”ë¡œ ë””ì§€í„¸ ê¸°ê¸° ì˜ì—­ì…ë‹ˆë‹¤.</td></tr>
<tr><td>If you think about the patient journey, oftentimes the very first thing you're doing is you're receiving some sort of imaging to understand what's going on in the body. So this is all your diagnostic imaging. You're measuring the biology, whether that's lab tests or genomic sequencing tests. And then you're going into some form of therapy that could be radiotherapy or could be robotic assisted. All of these sensors that these companies, great leaders in the industry, Siemens, GE, Intuitive Surgical, all of these are fantastic platforms and sensors that are going to become robotic in their own right.</td><td>í™˜ì ì—¬ì •ì„ ìƒê°í•´ë³´ë©´, ê°€ì¥ ë¨¼ì € í•˜ëŠ” ì¼ì€ ëŒ€ê°œ ì‹ ì²´ì—ì„œ ë¬´ì—‡ì´ ì¼ì–´ë‚˜ê³  ìˆëŠ”ì§€ íŒŒì•…í•˜ê¸° ìœ„í•´ ì–´ë–¤ í˜•íƒœì˜ ì˜ìƒ ì´¬ì˜ì„ ë°›ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ëª¨ë“  ì§„ë‹¨ ì˜ìƒì…ë‹ˆë‹¤. ì‹¤í—˜ì‹¤ ê²€ì‚¬ë“  ìœ ì „ì²´ ì‹œí€€ì‹± ê²€ì‚¬ë“  ìƒë¬¼í•™ì  ìƒíƒœë¥¼ ì¸¡ì •í•˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‚˜ì„œ ë°©ì‚¬ì„  ì¹˜ë£Œë‚˜ ë¡œë´‡ ë³´ì¡° ì¹˜ë£Œ ë“±ì˜ ì–´ë–¤ í˜•íƒœì˜ ì¹˜ë£Œë¡œ ë“¤ì–´ê°€ê²Œ ë©ë‹ˆë‹¤. ì§€ë©˜ìŠ¤, GE, ì¸íŠœì´í‹°ë¸Œ ì„œì§€ì»¬ ë“± ì—…ê³„ì˜ í›Œë¥­í•œ ì„ ë„ê¸°ì—…ë“¤ì´ ë³´ìœ í•œ ì´ ëª¨ë“  ì„¼ì„œë“¤ì€ ê·¸ ìì²´ë¡œ ë¡œë´‡í™”ë  í™˜ìƒì ì¸ í”Œë«í¼ì´ì ì„¼ì„œë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>They're not only going to sense what's going on, but they're going to reason over it and they're going to facilitate the ability for deeper understanding of our physicians. And so, digital devices is a huge area where itâ€™s going to continue to take advantage of these amazing agentic AI systems and future robotic systems. And digital biology, this is in the area of drug discovery. Right? We just actually added another $50 billion, Albert was here, $50 billion to a total of $300 billion is spent in R&D for drug discovery every single year. And we know we have extreme challenges here. We still have 90% attrition rate, when we get into clinical, we are generating more data than ever before.</td><td>ì´ë“¤ì€ ìƒí™©ì„ ê°ì§€í•  ë¿ë§Œ ì•„ë‹ˆë¼ ì´ë¥¼ ì¶”ë¡ í•˜ê³  ì˜ë£Œì§„ì˜ ë” ê¹Šì€ ì´í•´ë¥¼ ì´‰ì§„í•˜ëŠ” ëŠ¥ë ¥ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë””ì§€í„¸ ê¸°ê¸°ëŠ” ì´ëŸ¬í•œ ë†€ë¼ìš´ ì—ì´ì „í‹± AI ì‹œìŠ¤í…œê³¼ ë¯¸ë˜ì˜ ë¡œë´‡ ì‹œìŠ¤í…œì„ ì§€ì†ì ìœ¼ë¡œ í™œìš©í•  ìˆ˜ ìˆëŠ” ê±°ëŒ€í•œ ì˜ì—­ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë””ì§€í„¸ ìƒë¬¼í•™ì€ ì‹ ì•½ ê°œë°œ ë¶„ì•¼ì…ë‹ˆë‹¤. ë§ì£ ? ì‹¤ì œë¡œ ìš°ë¦¬ëŠ” ë°©ê¸ˆ 500ì–µ ë‹¬ëŸ¬ë¥¼ ì¶”ê°€í–ˆìŠµë‹ˆë‹¤. ì•Œë²„íŠ¸ê°€ ì—¬ê¸° ìˆì—ˆëŠ”ë°, ë§¤ë…„ ì‹ ì•½ ê°œë°œ R&Dì— ì´ 3,000ì–µ ë‹¬ëŸ¬ ì¤‘ 500ì–µ ë‹¬ëŸ¬ë¥¼ ì¶”ê°€í•œ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì´ ë¶„ì•¼ì—ì„œ ê·¹ì‹¬í•œ ë„ì „ì— ì§ë©´í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì„ìƒì‹œí—˜ì— ì§„ì…í•  ë•Œ ì—¬ì „íˆ 90%ì˜ ì‹¤íŒ¨ìœ¨ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ ë§ì€ ë°ì´í„°ë¥¼ ìƒì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is where we can take advantage of the AI breakthroughs thatâ€™s happened in language and apply it to the languages of drugs. So, just like our language, our spoken language is a sequence, actually biology is a sequence. Itâ€™s just in a very different shape. Itâ€™s three billion base pairs long is your DNA, amino acid sequence, for proteins and even SMILE strings for chemistry. But we can now start to use that to our advantage. All of the data we can now generate approximately 24 hours a day in these labs, we can start injecting those into these large language models, biology foundation models, to represent biology in profound new ways.</td><td>ì´ê²ƒì´ ë°”ë¡œ ì–¸ì–´ ë¶„ì•¼ì—ì„œ ì¼ì–´ë‚œ AI í˜ì‹ ì„ í™œìš©í•˜ì—¬ ì•½ë¬¼ì˜ ì–¸ì–´ì— ì ìš©í•  ìˆ˜ ìˆëŠ” ì§€ì ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì‚¬ìš©í•˜ëŠ” ì–¸ì–´, ì¦‰ ìŒì„± ì–¸ì–´ê°€ í•˜ë‚˜ì˜ ì‹œí€€ìŠ¤ì¸ ê²ƒì²˜ëŸ¼, ì‹¤ì œë¡œ ìƒë¬¼í•™ë„ ì‹œí€€ìŠ¤ì…ë‹ˆë‹¤. ë‹¤ë§Œ ë§¤ìš° ë‹¤ë¥¸ í˜•íƒœë¥¼ ë ê³  ìˆì„ ë¿ì…ë‹ˆë‹¤. DNAëŠ” 30ì–µ ê°œì˜ ì—¼ê¸°ìŒìœ¼ë¡œ ì´ë£¨ì–´ì ¸ ìˆê³ , ë‹¨ë°±ì§ˆì˜ ê²½ìš° ì•„ë¯¸ë…¸ì‚° ì„œì—´, ê·¸ë¦¬ê³  í™”í•™ì˜ ê²½ìš° SMILE ë¬¸ìì—´ë¡œ êµ¬ì„±ë˜ì–´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì œ ìš°ë¦¬ëŠ” ì´ë¥¼ ìš°ë¦¬ì—ê²Œ ìœ ë¦¬í•˜ê²Œ í™œìš©í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—°êµ¬ì‹¤ì—ì„œ í•˜ë£¨ ì•½ 24ì‹œê°„ ë™ì•ˆ ìƒì„±í•  ìˆ˜ ìˆëŠ” ëª¨ë“  ë°ì´í„°ë¥¼ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸, ì¦‰ ìƒë¬¼í•™ ê¸°ë°˜ ëª¨ë¸ì— ì£¼ì…í•˜ì—¬ ìƒë¬¼í•™ì„ ì™„ì „íˆ ìƒˆë¡œìš´ ë°©ì‹ìœ¼ë¡œ í‘œí˜„í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And weâ€™re seeing the R&D productivity massively increase. There is many examples SchrÃ¶dinger disrupting themselves in a way, using their own platform in fantastic ways to take what is otherwise years of work into ten months. And instead of synthesizing hundreds, if not thousands of chemicals, they are doing it on one or two orders of magnitude less. And so that R&D productivity is really profound. And then it doesnâ€™t just stop there in early discovery, it continues on into clinical development.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” R&D ìƒì‚°ì„±ì´ ëŒ€í­ ì¦ê°€í•˜ëŠ” ê²ƒì„ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìŠˆë¢°ë”©ê±°ê°€ ìì‚¬ì˜ í”Œë«í¼ì„ í™˜ìƒì ì¸ ë°©ì‹ìœ¼ë¡œ í™œìš©í•˜ì—¬ ìŠ¤ìŠ¤ë¡œë¥¼ í˜ì‹ í•˜ëŠ” ë§ì€ ì‚¬ë¡€ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ê¸°ì¡´ì— ìˆ˜ë…„ì´ ê±¸ë¦¬ë˜ ì‘ì—…ì„ 10ê°œì›”ë¡œ ë‹¨ì¶•ì‹œí‚¤ê³  ìˆì£ . ê·¸ë¦¬ê³  ìˆ˜ë°± ê°œ, ì‹¬ì§€ì–´ ìˆ˜ì²œ ê°œì˜ í™”í•™ë¬¼ì§ˆì„ í•©ì„±í•˜ëŠ” ëŒ€ì‹ , 1~2 ìë¦¿ìˆ˜ ì ì€ ìˆ˜ëŸ‰ìœ¼ë¡œ ì‘ì—…ì„ ìˆ˜í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ R&D ìƒì‚°ì„± í–¥ìƒì€ ì •ë§ ë†€ë¼ìš´ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì€ ì´ˆê¸° ë°œê²¬ ë‹¨ê³„ì—ì„œ ëë‚˜ì§€ ì•Šê³  ì„ìƒ ê°œë°œ ë‹¨ê³„ê¹Œì§€ ì§€ì†ë©ë‹ˆë‹¤.</td></tr>
<tr><td>We have friends here in the room who are acutely trying to tackle this problem of how can we do a better job using the language models to now strategize our clinical trial processes much better, find the patients, find the sites, design the trials, keep the patient engagement high, all of that now can be facilitated by todayâ€™s agentic AI. So, there is going to be amazing progress that is going to be felt there. And then the third one being digital health. Think of these as digital humans that you can hire on behalf of this otherwise completely stretched and burning out healthcare force that we have. We need to augment them with a digital health force and we now have the ability.</td><td>ì´ ìë¦¬ì—ëŠ” ì–¸ì–´ ëª¨ë¸ì„ í™œìš©í•˜ì—¬ ì„ìƒì‹œí—˜ í”„ë¡œì„¸ìŠ¤ë¥¼ ë³´ë‹¤ íš¨ê³¼ì ìœ¼ë¡œ ì „ëµí™”í•˜ê³ , í™˜ìë¥¼ ì°¾ê³ , ì‹œí—˜ ì¥ì†Œë¥¼ í™•ë³´í•˜ë©°, ì‹œí—˜ì„ ì„¤ê³„í•˜ê³ , í™˜ì ì°¸ì—¬ë„ë¥¼ ë†’ê²Œ ìœ ì§€í•˜ëŠ” ë“±ì˜ ë¬¸ì œë¥¼ ì ê·¹ì ìœ¼ë¡œ í•´ê²°í•˜ë ¤ëŠ” ë™ë£Œë“¤ì´ í•¨ê»˜ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì´ ì´ì œ ì˜¤ëŠ˜ë‚ ì˜ ì—ì´ì „í‹± AIë¥¼ í†µí•´ ì´‰ì§„ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë¶„ì•¼ì—ì„œ ë†€ë¼ìš´ ì§„ì „ì´ ì´ë£¨ì–´ì§ˆ ê²ƒì…ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ì„¸ ë²ˆì§¸ëŠ” ë””ì§€í„¸ í—¬ìŠ¤ì…ë‹ˆë‹¤. í˜„ì¬ ì™„ì „íˆ ê³¼ë¶€í•˜ ìƒíƒœì— ìˆê³  ë²ˆì•„ì›ƒì„ ê²ªê³  ìˆëŠ” ì˜ë£Œì§„ì„ ëŒ€ì‹ í•˜ì—¬ ê³ ìš©í•  ìˆ˜ ìˆëŠ” ë””ì§€í„¸ íœ´ë¨¼ìœ¼ë¡œ ìƒê°í•´ë³´ì‹­ì‹œì˜¤. ìš°ë¦¬ëŠ” ë””ì§€í„¸ í—¬ìŠ¤ ì¸ë ¥ìœ¼ë¡œ ê·¸ë“¤ì„ ë³´ê°•í•´ì•¼ í•˜ë©°, ì´ì œ ìš°ë¦¬ëŠ” ê·¸ëŸ´ ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ê°–ì¶”ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Hippocratic AI, one of our fantastic partners, just launched at the January health conference a whole agent AI marketplace, where instead of the software systems of the past, the electronic health records, which were huge software deployments, billions of dollars, huge change cost, huge training and change management necessary in the healthcare system, weâ€™re now in the phase of just like you and I as consumers, we can order groceries or use a service like Spotify on demand services, you can now augment the healthcare system and start to navigate it through on-demand digital â€“ human, digital health services. And so this is really, really fantastic.</td><td>ìš°ë¦¬ì˜ í›Œë¥­í•œ íŒŒíŠ¸ë„ˆ ì¤‘ í•˜ë‚˜ì¸ Hippocratic AIê°€ 1ì›” í—¬ìŠ¤ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ì™„ì „í•œ ì—ì´ì „íŠ¸ AI ë§ˆì¼“í”Œë ˆì´ìŠ¤ë¥¼ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ê³¼ê±°ì˜ ì†Œí”„íŠ¸ì›¨ì–´ ì‹œìŠ¤í…œë“¤, ì¦‰ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ëŒ€ê·œëª¨ ì†Œí”„íŠ¸ì›¨ì–´ ë°°í¬ì´ì ë§‰ëŒ€í•œ ë³€ê²½ ë¹„ìš©ê³¼ ì˜ë£Œ ì‹œìŠ¤í…œ ë‚´ ëŒ€ê·œëª¨ êµìœ¡ ë° ë³€í™” ê´€ë¦¬ê°€ í•„ìš”í–ˆë˜ ì „ì ê±´ê°• ê¸°ë¡ ì‹œìŠ¤í…œë“¤ê³¼ëŠ” ë‹¬ë¦¬, ì´ì œ ìš°ë¦¬ëŠ” ì†Œë¹„ìì¸ ì—¬ëŸ¬ë¶„ê³¼ ì œê°€ ì‹ë£Œí’ˆì„ ì£¼ë¬¸í•˜ê±°ë‚˜ Spotify ê°™ì€ ì˜¨ë””ë§¨ë“œ ì„œë¹„ìŠ¤ë¥¼ ì´ìš©í•˜ëŠ” ê²ƒì²˜ëŸ¼, ì´ì œ ì˜ë£Œ ì‹œìŠ¤í…œì„ ë³´ê°•í•˜ê³  ì˜¨ë””ë§¨ë“œ ë””ì§€í„¸ - íœ´ë¨¼, ë””ì§€í„¸ í—¬ìŠ¤ ì„œë¹„ìŠ¤ë¥¼ í†µí•´ ì˜ë£Œ ì‹œìŠ¤í…œì„ íƒìƒ‰í•  ìˆ˜ ìˆëŠ” ë‹¨ê³„ì— ì§„ì…í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì •ë§ë¡œ, ì •ë§ë¡œ í™˜ìƒì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And this is happening right now as we speak. And this is not a â€“ we are going to see this in three or five years. This is what weâ€™re going to see happen in the next three months. So, super excited about digital health. So those are really the three verticals that, I think, truly address a gigantic opportunity. Think about that $3 trillion of operating expenses in labor and how weâ€™re going to augment them. That can easily be a couple hundred billion dollars in what we call AI factory, AI infrastructure to support all of those agents, supporting the robotic surgeries of the future, supporting the digital biology labs of the future and supporting all of our healthcare workers.</td><td>ê·¸ë¦¬ê³  ì´ê²ƒì€ ì§€ê¸ˆ ì´ ìˆœê°„ì—ë„ ì¼ì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ 3ë…„ì´ë‚˜ 5ë…„ í›„ì— ë³´ê²Œ ë  ì¼ì´ ì•„ë‹™ë‹ˆë‹¤. ì´ê²ƒì€ ì•ìœ¼ë¡œ 3ê°œì›” ì•ˆì— ì¼ì–´ë‚  ì¼ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ë””ì§€í„¸ í—¬ìŠ¤ì¼€ì–´ì— ëŒ€í•´ ë§¤ìš° í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤. <br><br>ì´ ì„¸ ê°€ì§€ ìˆ˜ì§ ì˜ì—­ì´ì•¼ë§ë¡œ ê±°ëŒ€í•œ ê¸°íšŒë¥¼ ì§„ì •ìœ¼ë¡œ ë‹¤ë£¨ëŠ” ë¶„ì•¼ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë…¸ë™ë ¥ì— ì†Œìš”ë˜ëŠ” 3ì¡° ë‹¬ëŸ¬ì˜ ìš´ì˜ë¹„ìš©ê³¼ ìš°ë¦¬ê°€ ì´ë¥¼ ì–´ë–»ê²Œ ì¦ê°•ì‹œí‚¬ì§€ ìƒê°í•´ë³´ì‹­ì‹œì˜¤. ì´ëŠ” ìš°ë¦¬ê°€ AI íŒ©í† ë¦¬, ì¦‰ ëª¨ë“  ì—ì´ì „íŠ¸ë“¤ì„ ì§€ì›í•˜ê³ , ë¯¸ë˜ì˜ ë¡œë´‡ ìˆ˜ìˆ ì„ ì§€ì›í•˜ë©°, ë¯¸ë˜ì˜ ë””ì§€í„¸ ìƒë¬¼í•™ ì‹¤í—˜ì‹¤ì„ ì§€ì›í•˜ê³ , ëª¨ë“  ì˜ë£Œì§„ì„ ì§€ì›í•˜ëŠ” AI ì¸í”„ë¼ì—ì„œ ì‰½ê²Œ ìˆ˜ì²œì–µ ë‹¬ëŸ¬ ê·œëª¨ê°€ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So, this a gigantic opportunity? Brendan Smith<br><br>Yes, I think thatâ€™s a really super helpful lay of the different use cases for AI within healthcare that you just outlined. So, I want to double click maybe on health and biology aspects. So, maybe which types of research, diagnostic or clinical applications at this point do you see as particularly ripe for AI-driven innovation? And I guess what is it about those applications that might lead you to say that? Kimberly Powell<br><br>Yes, I think, that actually just recently Roche announced a new platform. When I was here last year, we had lots of new sequencing and genomics platforms.</td><td>ë¸Œë Œë˜ ìŠ¤ë¯¸ìŠ¤<br><br>ë„¤, ë°©ê¸ˆ ì„¤ëª…í•´ì£¼ì‹  í—¬ìŠ¤ì¼€ì–´ ë‚´ AIì˜ ë‹¤ì–‘í•œ í™œìš© ì‚¬ë¡€ë“¤ì´ ì •ë§ ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ê±´ê°• ë° ìƒë¬¼í•™ ì¸¡ë©´ì„ ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ê³  ì‹¶ì€ë°ìš”. í˜„ì¬ ì‹œì ì—ì„œ AI ê¸°ë°˜ í˜ì‹ ì— íŠ¹íˆ ì í•©í•˜ë‹¤ê³  ë³´ì‹œëŠ” ì—°êµ¬, ì§„ë‹¨ ë˜ëŠ” ì„ìƒ ì‘ìš© ë¶„ì•¼ëŠ” ì–´ë–¤ ê²ƒë“¤ì´ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ê·¸ëŸ¬í•œ ì‘ìš© ë¶„ì•¼ë“¤ì´ ê·¸ë ‡ê²Œ ìœ ë§í•˜ë‹¤ê³  íŒë‹¨í•˜ì‹œëŠ” ì´ìœ ëŠ” ë¬´ì—‡ì¸ê°€ìš”?<br><br>í‚´ë²Œë¦¬ íŒŒì›”<br><br>ë„¤, ì‹¤ì œë¡œ ìµœê·¼ì— ë¡œìŠˆ(Roche)ê°€ ìƒˆë¡œìš´ í”Œë«í¼ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì‘ë…„ì— ì œê°€ ì—¬ê¸° ì™”ì„ ë•ŒëŠ” ë§ì€ ìƒˆë¡œìš´ ì‹œí€€ì‹± ë° ìœ ì „ì²´í•™ í”Œë«í¼ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>There is still massive innovation in the ability to be able to read biology at incredibly new resolutions and at insane throughput. And genomics is just a very obvious one, because humans are just not built to read it or understand it. But what has just happened, in fact, I think, itâ€™s only a week old, we did some really groundbreaking work with the Arc Institute in California. We helped build the worldâ€™s largest biology foundation model for the first time. This biology foundation model is incredible. It was trained on some nine trillion nucleotides, it allows for a context length of one million, which is in some cases a whole genome of certain kind of species, bacteria.</td><td>ìƒë¬¼í•™ì„ ì „ë¡€ ì—†ëŠ” í•´ìƒë„ì™€ ì—„ì²­ë‚œ ì²˜ë¦¬ëŸ‰ìœ¼ë¡œ ì½ì–´ë‚¼ ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì—ëŠ” ì—¬ì „íˆ ëŒ€ê·œëª¨ í˜ì‹ ì´ ì¼ì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìœ ì „ì²´í•™ì€ ë§¤ìš° ëª…ë°±í•œ ì˜ˆì‹œì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì¸ê°„ì€ ì´ë¥¼ ì½ê±°ë‚˜ ì´í•´í•˜ë„ë¡ ë§Œë“¤ì–´ì§€ì§€ ì•Šì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë°©ê¸ˆ ì¼ì–´ë‚œ ì¼ì´ ìˆëŠ”ë°, ì‚¬ì‹¤ ì¼ì£¼ì¼ë°–ì— ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ìº˜ë¦¬í¬ë‹ˆì•„ì˜ Arc Instituteì™€ í•¨ê»˜ ì •ë§ íšê¸°ì ì¸ ì‘ì—…ì„ ìˆ˜í–‰í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì„¸ê³„ ìµœëŒ€ ê·œëª¨ì˜ ìƒë¬¼í•™ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ ìµœì´ˆë¡œ êµ¬ì¶•í•˜ëŠ” ë° ë„ì›€ì„ ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ ìƒë¬¼í•™ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì€ ì •ë§ ë†€ëìŠµë‹ˆë‹¤. ì•½ 9ì¡° ê°œì˜ ë‰´í´ë ˆì˜¤íƒ€ì´ë“œë¡œ í›ˆë ¨ë˜ì—ˆìœ¼ë©°, 100ë§Œ ê°œì˜ ì»¨í…ìŠ¤íŠ¸ ê¸¸ì´ë¥¼ í—ˆìš©í•©ë‹ˆë‹¤. ì´ëŠ” ê²½ìš°ì— ë”°ë¼ì„œëŠ” íŠ¹ì • ì¢…ë¥˜ì˜ ì¢…, ì¦‰ ë°•í…Œë¦¬ì•„ì˜ ì „ì²´ ê²Œë†ˆì— í•´ë‹¹í•©ë‹ˆë‹¤.</td></tr>
<tr><td>These are the domain-specific things that we need to work on in order to take the breakthroughs of large language models and transition them into the areas of biology. And so what is really happening here when you can study genomes from all these different species, you create a representation of biology that now allows for a study of the biology, and understanding of the biology in incredible new ways and in fact can predict variants at extreme accuracy, like they proved with the BRCA1 genomic variant. But this model can also do some other incredibly exciting things like write biology. So, you went from, okay, weâ€™re still creating new platforms that can read biology at new scales.</td><td>ì´ëŸ¬í•œ ê²ƒë“¤ì€ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸ì˜ í˜ì‹ ì  ì„±ê³¼ë¥¼ ìƒë¬¼í•™ ë¶„ì•¼ë¡œ ì „í™˜í•˜ê¸° ìœ„í•´ ìš°ë¦¬ê°€ ì‘ì—…í•´ì•¼ í•˜ëŠ” ë„ë©”ì¸ë³„ íŠ¹í™” ì˜ì—­ë“¤ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ëª¨ë“  ë‹¤ì–‘í•œ ì¢…ì˜ ê²Œë†ˆì„ ì—°êµ¬í•  ìˆ˜ ìˆê²Œ ë˜ë©´, ìƒë¬¼í•™ì— ëŒ€í•œ í‘œí˜„ì„ ë§Œë“¤ì–´ë‚´ê²Œ ë˜ê³ , ì´ëŠ” ì´ì œ ë†€ë¼ìš¸ ì •ë„ë¡œ ìƒˆë¡œìš´ ë°©ì‹ìœ¼ë¡œ ìƒë¬¼í•™ì„ ì—°êµ¬í•˜ê³  ì´í•´í•  ìˆ˜ ìˆê²Œ í•´ì£¼ë©°, ì‹¤ì œë¡œ BRCA1 ê²Œë†ˆ ë³€ì´ë¡œ ì…ì¦í•œ ë°”ì™€ ê°™ì´ ê·¹ë„ë¡œ ì •í™•í•˜ê²Œ ë³€ì´ë¥¼ ì˜ˆì¸¡í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ ëª¨ë¸ì€ ìƒë¬¼í•™ì„ ì‘ì„±í•˜ëŠ” ê²ƒê³¼ ê°™ì€ ë‹¤ë¥¸ ë†€ë¼ìš¸ ì •ë„ë¡œ í¥ë¯¸ì§„ì§„í•œ ì¼ë“¤ë„ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì—¬ì „íˆ ìƒˆë¡œìš´ ê·œëª¨ë¡œ ìƒë¬¼í•™ì„ ì½ì„ ìˆ˜ ìˆëŠ” ìƒˆë¡œìš´ í”Œë«í¼ì„ ë§Œë“¤ì–´ë‚´ê³  ìˆë‹¤ëŠ” ìƒí™©ì—ì„œ ì¶œë°œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We now have the ability to write biology and we also need these models to help us really do the analysis and understand the inner workings of biology. And so there's a lot of people in this room who I know are thinking about it.</td><td>ì´ì œ ìš°ë¦¬ëŠ” ìƒë¬¼í•™ì„ ì‘ì„±í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ê°–ì¶”ì—ˆìœ¼ë©°, ìƒë¬¼í•™ì˜ ë‚´ë¶€ ì‘ë™ ì›ë¦¬ë¥¼ ë¶„ì„í•˜ê³  ì´í•´í•˜ëŠ” ë° ë„ì›€ì´ ë˜ëŠ” ì´ëŸ¬í•œ ëª¨ë¸ë“¤ì´ í•„ìš”í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ìë¦¬ì— ê³„ì‹  ë§ì€ ë¶„ë“¤ì´ ì´ì— ëŒ€í•´ ìƒê°í•˜ê³  ê³„ì‹ ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This idea is, how could we eventually get to what's called the virtual cell, the AI virtual cell, where you're able to now maybe represent biology at multi levels and then be able to have these AI models, be able to reason across these multi scales and connect what is a very complicated, the world's probably most complicated, study of biology to not only understand all of the molecules that's going inside cell, but also cell to cell cellular systems all the way up to organ. And so we have a lot of work to do there.</td><td>ì´ ì•„ì´ë””ì–´ëŠ” ê²°êµ­ ê°€ìƒ ì„¸í¬, ì¦‰ AI ê°€ìƒ ì„¸í¬ë¼ê³  ë¶ˆë¦¬ëŠ” ê²ƒì— ì–´ë–»ê²Œ ë„ë‹¬í•  ìˆ˜ ìˆì„ì§€ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì—¬ê¸°ì„œëŠ” ìƒë¬¼í•™ì„ ë‹¤ì¤‘ ë ˆë²¨ì—ì„œ í‘œí˜„í•  ìˆ˜ ìˆê²Œ ë˜ê³ , ì´ëŸ¬í•œ AI ëª¨ë¸ë“¤ì´ ë‹¤ì¤‘ ìŠ¤ì¼€ì¼ì— ê±¸ì³ ì¶”ë¡ í•˜ê³ , ì„¸ê³„ì—ì„œ ì•„ë§ˆë„ ê°€ì¥ ë³µì¡í•œ ìƒë¬¼í•™ ì—°êµ¬ë¥¼ ì—°ê²°í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì„¸í¬ ë‚´ë¶€ì˜ ëª¨ë“  ë¶„ìë“¤ì„ ì´í•´í•  ë¿ë§Œ ì•„ë‹ˆë¼, ì„¸í¬ ê°„ ì„¸í¬ ì‹œìŠ¤í…œë¶€í„° ì¥ê¸°ì— ì´ë¥´ê¸°ê¹Œì§€ ëª¨ë“  ê²ƒì„ íŒŒì•…í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ì—ê²ŒëŠ” í•´ì•¼ í•  ì¼ì´ ë§ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So it's absolutely ripe and it's one of our fastest growing areas in fact is helping the pharmaceutical industry, this burgeoning sort of tech bio industry, which is coming at it from what data can I generate? What can I measure? And then how can I represent it in models to then drive what kind of medicines we can go after? And so there's model-driven drug discovery and molecular discovery. And then we also need to say, how can we do model-driven biology discovery? Because we all know that we need to also expand our understanding of targets. And so those two things are absolutely right. So ripe in the areas of being able to measure it, read it, write it.</td><td>ë”°ë¼ì„œ ì´ ë¶„ì•¼ëŠ” ì™„ì „íˆ ì„±ìˆ™í•œ ì‹œì ì— ìˆìœ¼ë©°, ì‹¤ì œë¡œ ì œì•½ ì‚°ì—…ì„ ì§€ì›í•˜ëŠ” ê²ƒì´ ì €í¬ì˜ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì˜ì—­ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. íŠ¹íˆ ê¸‰ì„±ì¥í•˜ê³  ìˆëŠ” í…Œí¬ ë°”ì´ì˜¤ ì‚°ì—…ì„ ì§€ì›í•˜ê³  ìˆëŠ”ë°, ì´ë“¤ì€ 'ì–´ë–¤ ë°ì´í„°ë¥¼ ìƒì„±í•  ìˆ˜ ìˆëŠ”ê°€? ë¬´ì—‡ì„ ì¸¡ì •í•  ìˆ˜ ìˆëŠ”ê°€? ê·¸ë¦¬ê³  ì´ë¥¼ ëª¨ë¸ë¡œ ì–´ë–»ê²Œ í‘œí˜„í•˜ì—¬ ì–´ë–¤ ì¢…ë¥˜ì˜ ì˜ì•½í’ˆì„ ì¶”êµ¬í•  ìˆ˜ ìˆì„ì§€ ê²°ì •í•  ìˆ˜ ìˆëŠ”ê°€?'ë¼ëŠ” ê´€ì ì—ì„œ ì ‘ê·¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ëª¨ë¸ ê¸°ë°˜ ì‹ ì•½ ë°œê²¬ê³¼ ë¶„ì ë°œê²¬ì´ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” 'ëª¨ë¸ ê¸°ë°˜ ìƒë¬¼í•™ì  ë°œê²¬ì„ ì–´ë–»ê²Œ í•  ìˆ˜ ìˆëŠ”ê°€?'ë¼ê³  ë¬¼ì–´ì•¼ í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì €í¬ ëª¨ë‘ íƒ€ê²Ÿì— ëŒ€í•œ ì´í•´ë¥¼ í™•ì¥í•´ì•¼ í•œë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ ë‘ ê°€ì§€ ëª¨ë‘ ì™„ì „íˆ ì ì ˆí•œ ì‹œì ì— ìˆìŠµë‹ˆë‹¤. ì¸¡ì •í•˜ê³ , ì½ê³ , ì“¸ ìˆ˜ ìˆëŠ” ì˜ì—­ì—ì„œ ì„±ìˆ™í•œ ì‹œì ì— ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And so that is really just starting to come into view here. So super exciting. Brendan Smith<br><br>So I guess specifically within the drug discovery piece of what you covered there, I guess, what do you feel people fundamentally either misunderstand or underappreciate about the applications for AI that are already happening today? Kimberly Powell<br><br>Yes, I love. Thank you for asking that question, because it's something that we were thinking a lot about actually during COVID as Albert [ph]was saying, we saw what was essentially what feels like a missed opportunity in that, that $300 billion of R& D spend.</td><td>ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ì§€ê¸ˆ ì‹œì•¼ì— ë“¤ì–´ì˜¤ê¸° ì‹œì‘í•˜ëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ì •ë§ í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤.<br><br>ë¸Œë Œë“  ìŠ¤ë¯¸ìŠ¤<br><br>ë°©ê¸ˆ ë§ì”€í•˜ì‹  ë‚´ìš© ì¤‘ ì‹ ì•½ ê°œë°œ ë¶€ë¶„ì— ëŒ€í•´ êµ¬ì²´ì ìœ¼ë¡œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ì‹¤ì œë¡œ ì¼ì–´ë‚˜ê³  ìˆëŠ” AI ì‘ìš© ë¶„ì•¼ì— ëŒ€í•´ ì‚¬ëŒë“¤ì´ ê·¼ë³¸ì ìœ¼ë¡œ ì˜¤í•´í•˜ê±°ë‚˜ ê³¼ì†Œí‰ê°€í•˜ê³  ìˆëŠ” ë¶€ë¶„ì´ ë¬´ì—‡ì´ë¼ê³  ìƒê°í•˜ì‹­ë‹ˆê¹Œ?<br><br>í‚´ë²Œë¦¬ íŒŒì›”<br><br>ë„¤, ì¢‹ì€ ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì‹¤ì œë¡œ ì½”ë¡œë‚˜19 ê¸°ê°„ ë™ì•ˆ ì €í¬ê°€ ë§ì´ ìƒê°í–ˆë˜ ë¶€ë¶„ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì•Œë²„íŠ¸ê°€ ë§í–ˆë“¯ì´, ì €í¬ëŠ” ë³¸ì§ˆì ìœ¼ë¡œ ë†“ì¹œ ê¸°íšŒì²˜ëŸ¼ ëŠê»´ì§€ëŠ” ê²ƒì„ ëª©ê²©í–ˆìŠµë‹ˆë‹¤. ë°”ë¡œ ê·¸ 3,000ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ R&D ì§€ì¶œ ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>A substantial amount of it is in what's very artisanal, very deep domain expertise, experimental processes, lab work, for the lack of better words. This is the IP of most biotech, tech-bio, pharmaceutical companies. And we could, we were witnessing that they just were not taking enough advantage of it. And so with our collaborators in the industry, you could imagine that what is happening now is, how can we create the conditions that AI is in the loop or lab is in the loop with AI.</td><td>ìƒë‹¹ ë¶€ë¶„ì´ ë§¤ìš° ì¥ì¸ì ì´ê³ , ë§¤ìš° ê¹Šì€ ë„ë©”ì¸ ì „ë¬¸ì„±, ì‹¤í—˜ì  í”„ë¡œì„¸ìŠ¤, ì‹¤í—˜ì‹¤ ì‘ì—…ì— ìˆìŠµë‹ˆë‹¤. ë” ë‚˜ì€ í‘œí˜„ì´ ì—†ì–´ì„œ ì´ë ‡ê²Œ ë§ì”€ë“œë¦¬ëŠ”ë°, ì´ê²ƒì´ ëŒ€ë¶€ë¶„ì˜ ë°”ì´ì˜¤í…Œí¬, í…Œí¬-ë°”ì´ì˜¤, ì œì•½íšŒì‚¬ë“¤ì˜ ì§€ì ì¬ì‚°ê¶Œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì´ë“¤ì´ ì´ë¥¼ ì¶©ë¶„íˆ í™œìš©í•˜ì§€ ëª»í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ëª©ê²©í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì—…ê³„ì˜ í˜‘ë ¥ì—…ì²´ë“¤ê³¼ í•¨ê»˜, ì§€ê¸ˆ ì¼ì–´ë‚˜ê³  ìˆëŠ” ê²ƒì€ ì–´ë–»ê²Œ í•˜ë©´ AIê°€ ë£¨í”„ì— í¬í•¨ë˜ê±°ë‚˜ ì‹¤í—˜ì‹¤ì´ AIì™€ í•¨ê»˜ ë£¨í”„ì— í¬í•¨ë˜ëŠ” ì¡°ê±´ì„ ë§Œë“¤ ìˆ˜ ìˆì„ì§€ì— ëŒ€í•œ ê²ƒì´ë¼ê³  ìƒìƒí•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So every single experiment that you do, every idea your scientist has, can now be captured and codified to build upon an institutional knowledge that otherwise is maybe sitting in an electronic lab notebook somewhere. But how could you represent even those decades of electronic lab notebooks in a model? And then every single experiment you make, put it back in. And so we've invented a platform called BioNeMo to serve just that. And you see the reason I talked about these three scaling laws is, because this lab in the loop is essentially going to require all three of those. It's going to require the very large-scale pre-training of these very large foundational models.</td><td>ë”°ë¼ì„œ ì—¬ëŸ¬ë¶„ì˜ ê³¼í•™ìê°€ ìˆ˜í–‰í•˜ëŠ” ëª¨ë“  ì‹¤í—˜, ëª¨ë“  ì•„ì´ë””ì–´ë¥¼ ì´ì œ í¬ì°©í•˜ê³  ì²´ê³„í™”í•˜ì—¬ ê¸°ê´€ì˜ ì§€ì‹ ê¸°ë°˜ì„ êµ¬ì¶•í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ì§€ ì•Šìœ¼ë©´ ì´ëŸ¬í•œ ì§€ì‹ë“¤ì´ ì–´ë”˜ê°€ì˜ ì „ì ì‹¤í—˜ ë…¸íŠ¸ë¶ì—ë§Œ ì €ì¥ë˜ì–´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìˆ˜ì‹­ ë…„ê°„ì˜ ì „ì ì‹¤í—˜ ë…¸íŠ¸ë¶ë“¤ì„ ì–´ë–»ê²Œ ëª¨ë¸ë¡œ í‘œí˜„í•  ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ì´ ìˆ˜í–‰í•˜ëŠ” ëª¨ë“  ì‹¤í—˜ì„ ë‹¤ì‹œ ê·¸ ëª¨ë¸ì— ì…ë ¥í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ ìœ„í•´ ìš°ë¦¬ëŠ” BioNeMoë¼ëŠ” í”Œë«í¼ì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤. <br><br>ì œê°€ ì´ ì„¸ ê°€ì§€ ìŠ¤ì¼€ì¼ë§ ë²•ì¹™ì— ëŒ€í•´ ë§ì”€ë“œë¦° ì´ìœ ëŠ”, ì´ëŸ¬í•œ lab in the loop(ì‹¤í—˜ì‹¤ ì—°ë™) ë°©ì‹ì´ ë³¸ì§ˆì ìœ¼ë¡œ ì´ ì„¸ ê°€ì§€ ëª¨ë‘ë¥¼ í•„ìš”ë¡œ í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° ëŒ€ê·œëª¨ì˜ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ë“¤ì— ëŒ€í•œ ëŒ€ê·œëª¨ ì‚¬ì „ í›ˆë ¨ì„ í•„ìš”ë¡œ í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Tens of billions, hundreds of billions of parameters. We just reached, $40 billion with this latest foundation model we built. You're then going to take that model and you're going to use it to do all sorts of tasks, generate ideas the scientists otherwise wouldn't. And then you have to prune those down, you have to use prediction models to prune those down. And then you might want to even optimize them before they go into the lab. So you're doing all of this AI work upstream of the lab. After you go into the lab, you take all that very, very high value, essentially gold standard data and you get it back into the model and you go through this loop again and again.</td><td>ìˆ˜ì‹­ì–µ, ìˆ˜ë°±ì–µ ê°œì˜ ë§¤ê°œë³€ìˆ˜ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ êµ¬ì¶•í•œ ì´ë²ˆ ìµœì‹  íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ë¡œ 400ì–µ ë‹¬ëŸ¬ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. ê·¸ ë‹¤ìŒì—ëŠ” ê·¸ ëª¨ë¸ì„ ê°€ì ¸ì™€ì„œ ê³¼í•™ìë“¤ì´ ë‹¬ë¦¬ ìƒê°í•´ë‚´ì§€ ëª»í–ˆì„ ì•„ì´ë””ì–´ë¥¼ ìƒì„±í•˜ëŠ” ë“± ì˜¨ê°– ì‘ì—…ì— í™œìš©í•˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ëŸ° ë‹¤ìŒ ê·¸ê²ƒë“¤ì„ ì •ì œí•´ì•¼ í•˜ê³ , ì˜ˆì¸¡ ëª¨ë¸ì„ ì‚¬ìš©í•´ì„œ ì •ì œí•´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹¤í—˜ì‹¤ë¡œ ë³´ë‚´ê¸° ì „ì— ìµœì í™”ê¹Œì§€ í•˜ê³  ì‹¶ì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì‹¤í—˜ì‹¤ ì—…ìŠ¤íŠ¸ë¦¼ì—ì„œ ì´ ëª¨ë“  AI ì‘ì—…ì„ ìˆ˜í–‰í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì‹¤í—˜ì‹¤ì— ë“¤ì–´ê°„ í›„ì—ëŠ” ë§¤ìš° ë†’ì€ ê°€ì¹˜ì˜, ë³¸ì§ˆì ìœ¼ë¡œ ê³¨ë“œ ìŠ¤íƒ ë‹¤ë“œ ë°ì´í„°ë¥¼ ëª¨ë‘ ê°€ì ¸ì™€ì„œ ëª¨ë¸ì— ë‹¤ì‹œ ì…ë ¥í•˜ê³  ì´ ë£¨í”„ë¥¼ ê³„ì†í•´ì„œ ë°˜ë³µí•˜ê²Œ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>And that is what is really starting to shrink. What is otherwise a five or three-year process. We're talking months now. And the readouts from the industry are happening very often. And so I think it was very underappreciated. They know their data is valuable. They didn't realize that they could put it in a model where it would be completely reproducible, reusable. Build upon this institutional knowledge and let's face it, this industry is a challenging one because it's very transient.</td><td>ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ì‹¤ì œë¡œ ë‹¨ì¶•ë˜ê¸° ì‹œì‘í•˜ê³  ìˆëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ì›ë˜ 5ë…„ ë˜ëŠ” 3ë…„ì´ ê±¸ë¦¬ë˜ í”„ë¡œì„¸ìŠ¤ë¥¼ ì´ì œ ëª‡ ê°œì›” ë‹¨ìœ„ë¡œ ì´ì•¼ê¸°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—…ê³„ë¡œë¶€í„°ì˜ ê²°ê³¼ë“¤ì´ ë§¤ìš° ë¹ˆë²ˆí•˜ê²Œ ë‚˜ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ ë§¤ìš° ê³¼ì†Œí‰ê°€ë˜ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë“¤ì€ ìì‹ ë“¤ì˜ ë°ì´í„°ê°€ ê°€ì¹˜ ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ë“¤ì´ ê·¸ ë°ì´í„°ë¥¼ ì™„ì „íˆ ì¬í˜„ ê°€ëŠ¥í•˜ê³  ì¬ì‚¬ìš© ê°€ëŠ¥í•œ ëª¨ë¸ì— ë„£ì„ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì„ ê¹¨ë‹«ì§€ ëª»í–ˆë˜ ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°ê´€ì  ì§€ì‹ì„ ë°”íƒ•ìœ¼ë¡œ êµ¬ì¶•í•˜ëŠ” ê²ƒì´ê³ , ì†”ì§íˆ ë§í•´ì„œ ì´ ì—…ê³„ëŠ” ë§¤ìš° ìœ ë™ì ì´ê¸° ë•Œë¬¸ì— ë„ì „ì ì¸ ì—…ê³„ì…ë‹ˆë‹¤.</td></tr>
<tr><td>The scientists are jumping from one company to another and you have the potential to lose that deep domain expertise or that deep level of understanding when you can represent in models, it's now there for your company, your enterprise, to extract the most value out of it. And so I'm super excited about that. And you see the work that we're doing with Genentech and our friends here, relation lab in the loop is absolutely how R&D should be conducted. Capture every ounce of data that is so high value to teach us how to make the best next scientific decision. And we're right at the cusp of having AI scientists.</td><td>ê³¼í•™ìë“¤ì´ í•œ íšŒì‚¬ì—ì„œ ë‹¤ë¥¸ íšŒì‚¬ë¡œ ì´ì§í•˜ë©´ì„œ ê·¸ ê¹Šì€ ë„ë©”ì¸ ì „ë¬¸ì„±ì´ë‚˜ ê¹Šì€ ìˆ˜ì¤€ì˜ ì´í•´ë¥¼ ìƒì„ ê°€ëŠ¥ì„±ì´ ìˆëŠ”ë°, ì´ì œ ì´ë¥¼ ëª¨ë¸ë¡œ í‘œí˜„í•  ìˆ˜ ìˆê²Œ ë˜ë©´ì„œ ê·€í•˜ì˜ íšŒì‚¬, ê·€í•˜ì˜ ê¸°ì—…ì´ ì´ë¡œë¶€í„° ìµœëŒ€í•œì˜ ê°€ì¹˜ë¥¼ ì¶”ì¶œí•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì €ëŠ” ì´ì— ëŒ€í•´ ë§¤ìš° í¥ë¯¸ì§„ì§„í•˜ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ì œë„¨í…(Genentech)ê³¼ í•¨ê»˜ í•˜ê³  ìˆëŠ” ì‘ì—…ê³¼ ì—¬ê¸° ì €í¬ íŒŒíŠ¸ë„ˆì¸ ë¦´ë ˆì´ì…˜ ë©(Relation Lab)ê³¼ì˜ í˜‘ì—…ì„ ë³´ì‹œë©´, ë£¨í”„ ì•ˆì—ì„œì˜ ì´ëŸ° ë°©ì‹ì´ì•¼ë§ë¡œ R&Dê°€ ìˆ˜í–‰ë˜ì–´ì•¼ í•˜ëŠ” ë°©ë²•ì…ë‹ˆë‹¤. ìµœê³ ì˜ ë‹¤ìŒ ê³¼í•™ì  ì˜ì‚¬ê²°ì •ì„ ë‚´ë¦¬ëŠ” ë°©ë²•ì„ ê°€ë¥´ì³ì£¼ëŠ” ë§¤ìš° ë†’ì€ ê°€ì¹˜ì˜ ëª¨ë“  ë°ì´í„°ë¥¼ í¬ì°©í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì§€ê¸ˆ AI ê³¼í•™ìë¥¼ ë³´ìœ í•˜ê²Œ ë˜ëŠ” ì „í™˜ì ì— ì„œ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Fantastic papers have just recently been published where, you're going to be a biologist, you're just going to talk to the computer, you're going to, you're going to banter with it, you're going to hypothesize with it, it's going to automatically, go off and run some experiments for you, come back, synthesize what it witnessed in those experiments and you're going to have dynamic conversations with the AIs. And so that's coming and it's really exciting. Josh Buchalter<br><br>I wanted to follow up on BioNeMo actually. So in the tech community we've become used to sort of an arms race to build foundational LLMs.</td><td>ìµœê·¼ì— ë°œí‘œëœ ë†€ë¼ìš´ ë…¼ë¬¸ë“¤ì„ ë³´ë©´, ìƒë¬¼í•™ìê°€ ì»´í“¨í„°ì™€ ëŒ€í™”í•˜ë“¯ ì†Œí†µí•˜ê³ , ë†ë‹´ì„ ì£¼ê³ ë°›ìœ¼ë©°, ê°€ì„¤ì„ ì„¸ìš°ë©´ AIê°€ ìë™ìœ¼ë¡œ ì‹¤í—˜ì„ ì§„í–‰í•˜ê³  ëŒì•„ì™€ì„œ ì‹¤í—˜ì—ì„œ ê´€ì°°í•œ ë‚´ìš©ì„ ì¢…í•©í•´ì£¼ëŠ” ë°©ì‹ìœ¼ë¡œ AIì™€ ì—­ë™ì ì¸ ëŒ€í™”ë¥¼ ë‚˜ëˆŒ ìˆ˜ ìˆê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ° ë¯¸ë˜ê°€ ë‹¤ê°€ì˜¤ê³  ìˆìœ¼ë©° ì •ë§ í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤.<br><br>Josh Buchalter<br><br>ì‹¤ì œë¡œ BioNeMoì— ëŒ€í•´ í›„ì† ì§ˆë¬¸ì„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ê¸°ìˆ  ì»¤ë®¤ë‹ˆí‹°ì—ì„œëŠ” ê¸°ì´ˆ LLM êµ¬ì¶•ì„ ìœ„í•œ ì¼ì¢…ì˜ êµ°ë¹„ê²½ìŸì— ìµìˆ™í•´ì ¸ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But with BioNeMo it seems like NVIDIA is doing more of that work on behalf of and in partnership with your customers. Is that the right way to think about the go-to-market and your relationship specifically in digital biology? And then I guess on that note, given how critical data sovereignty and ownership and creation and capture is, how does that work given how much of the frontier model or I'm calling it a frontier model development you're doing with BioNeMo? Kimberly Powell<br><br>Yes, I appreciate that question also very much. We are 100% an ecosystem and platform go-to-market. We train some biology foundation models to understand the process.</td><td>í•˜ì§€ë§Œ BioNeMoì˜ ê²½ìš° NVIDIAê°€ ê³ ê°ë“¤ì„ ëŒ€ì‹ í•´ì„œ ê·¸ë¦¬ê³  ê³ ê°ë“¤ê³¼ì˜ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ ë” ë§ì€ ì‘ì—…ì„ ìˆ˜í–‰í•˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë””ì§€í„¸ ìƒë¬¼í•™ ë¶„ì•¼ì—ì„œì˜ ì‹œì¥ ì§„ì¶œ ë°©ì‹ê³¼ ê´€ê³„ì— ëŒ€í•œ ì˜¬ë°”ë¥¸ ì´í•´ì¸ê°€ìš”? ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨í•´ì„œ, ë°ì´í„° ì£¼ê¶Œê³¼ ì†Œìœ ê¶Œ, ìƒì„± ë° í¬ì°©ì´ ì–¼ë§ˆë‚˜ ì¤‘ìš”í•œì§€ë¥¼ ê³ ë ¤í•  ë•Œ, BioNeMoë¥¼ í†µí•´ ìˆ˜í–‰í•˜ê³  ìˆëŠ” í”„ë¡ í‹°ì–´ ëª¨ë¸ ê°œë°œ ì‘ì—…ì´ ìƒë‹¹í•œ ìƒí™©ì—ì„œ ì´ê²ƒì´ ì–´ë–»ê²Œ ì‘ë™í•˜ëŠ” ê±´ê°€ìš”?<br><br>í‚´ë²Œë¦¬ íŒŒì›”<br><br>ë„¤, ê·¸ ì§ˆë¬¸ë„ ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ëŠ” 100% ìƒíƒœê³„ì™€ í”Œë«í¼ ì¤‘ì‹¬ì˜ ì‹œì¥ ì§„ì¶œ ë°©ì‹ì„ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í”„ë¡œì„¸ìŠ¤ë¥¼ ì´í•´í•˜ê¸° ìœ„í•´ ì¼ë¶€ ìƒë¬¼í•™ ê¸°ë°˜ ëª¨ë¸ë“¤ì„ í›ˆë ¨ì‹œí‚µë‹ˆë‹¤.</td></tr>
<tr><td>The end-to-end life cycle of building these models is extremely complex. We are in that business to codify that process into a platform like BioNeMo and give it to the industry for exactly that reason. Their data is their IP and should remain that forever. So how can we build enough of a foundation model that we took some of the hard work out? We codify, okay, how do you have to process the data beforehand? What model architectures are needed? How do you shard that model up across a data center of thousands of GPUs to train it in the shortest amount of time and cost footprint, total cost of ownership of training those models?</td><td>ì´ëŸ¬í•œ ëª¨ë¸ë“¤ì„ êµ¬ì¶•í•˜ëŠ” ì „ì²´ ìƒëª…ì£¼ê¸°ëŠ” ê·¹ë„ë¡œ ë³µì¡í•©ë‹ˆë‹¤. ì €í¬ëŠ” ë°”ë¡œ ê·¸ëŸ° ì´ìœ ë¡œ ì´ ê³¼ì •ì„ BioNeMoì™€ ê°™ì€ í”Œë«í¼ìœ¼ë¡œ ì²´ê³„í™”í•˜ì—¬ ì—…ê³„ì— ì œê³µí•˜ëŠ” ì‚¬ì—…ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì˜ ë°ì´í„°ëŠ” ê·¸ë“¤ì˜ ì§€ì ì¬ì‚°ì´ë©° ì˜ì›íˆ ê·¸ë˜ì•¼ í•©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì–´ë–»ê²Œ í•˜ë©´ ì–´ë ¤ìš´ ì‘ì—…ì˜ ì¼ë¶€ë¥¼ ëœì–´ë‚¼ ìˆ˜ ìˆëŠ” ì¶©ë¶„í•œ ê¸°ë°˜ ëª¨ë¸ì„ êµ¬ì¶•í•  ìˆ˜ ìˆì„ê¹Œìš”? ì €í¬ëŠ” ì´ë¥¼ ì²´ê³„í™”í•©ë‹ˆë‹¤. ë°ì´í„°ë¥¼ ì‚¬ì „ì— ì–´ë–»ê²Œ ì²˜ë¦¬í•´ì•¼ í•˜ëŠ”ì§€, ì–´ë–¤ ëª¨ë¸ ì•„í‚¤í…ì²˜ê°€ í•„ìš”í•œì§€, ìˆ˜ì²œ ê°œì˜ GPUë¡œ êµ¬ì„±ëœ ë°ì´í„°ì„¼í„° ì „ë°˜ì— ê±¸ì³ í•´ë‹¹ ëª¨ë¸ì„ ì–´ë–»ê²Œ ìƒ¤ë”©í•˜ì—¬ ìµœë‹¨ ì‹œê°„ê³¼ ë¹„ìš©ìœ¼ë¡œ, ì¦‰ ì´ëŸ¬í•œ ëª¨ë¸ë“¤ì„ í›ˆë ¨í•˜ëŠ” ì´ì†Œìœ ë¹„ìš©ì„ ìµœì†Œí™”í•˜ë©´ì„œ í›ˆë ¨í•  ìˆ˜ ìˆëŠ”ì§€ë¥¼ ì²´ê³„í™”í•©ë‹ˆë‹¤.</td></tr>
<tr><td>How do you then package those models so that you can put them into production, with, again, the lowest cost, to run it? That whole process is what we essentially build into BioNeMo, and we give it to our friends like Relation or Genentech, and, and they train their own models. And so that is our go-to-market is in the, the BioNeMo platform being a platform that can, be deployed anywhere it would like, on-prem, in a public cloud, in a supercomputing center somewhere, right next to an instrument. It's really completely versatile, but we turn it into tools that are much, much easier to use and we take a lot of the hard computer science and, and we codify the data science know how.</td><td>ê·¸ë ‡ë‹¤ë©´ ì´ëŸ¬í•œ ëª¨ë¸ë“¤ì„ ì–´ë–»ê²Œ íŒ¨í‚¤ì§•í•˜ì—¬ ë‹¤ì‹œ ê°€ì¥ ë‚®ì€ ë¹„ìš©ìœ¼ë¡œ í”„ë¡œë•ì…˜ì— íˆ¬ì…í•  ìˆ˜ ìˆì„ê¹Œìš”? ì´ ì „ì²´ í”„ë¡œì„¸ìŠ¤ê°€ ë°”ë¡œ ìš°ë¦¬ê°€ BioNeMoì— êµ¬ì¶•í•œ í•µì‹¬ì´ë©°, ì´ë¥¼ Relationì´ë‚˜ Genentech ê°™ì€ íŒŒíŠ¸ë„ˆë“¤ì—ê²Œ ì œê³µí•˜ì—¬ ê·¸ë“¤ì´ ìì²´ ëª¨ë¸ì„ í›ˆë ¨í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ì˜ ì‹œì¥ ì§„ì¶œ ì „ëµì€ BioNeMo í”Œë«í¼ì„ ì˜¨í”„ë ˆë¯¸ìŠ¤, í¼ë¸”ë¦­ í´ë¼ìš°ë“œ, ì–´ë”˜ê°€ì˜ ìŠˆí¼ì»´í“¨íŒ… ì„¼í„°, ë˜ëŠ” ì¥ë¹„ ë°”ë¡œ ì˜† ë“± ì›í•˜ëŠ” ì–´ëŠ ê³³ì—ë“  ë°°í¬í•  ìˆ˜ ìˆëŠ” í”Œë«í¼ìœ¼ë¡œ ì œê³µí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì •ë§ë¡œ ì™„ì „íˆ ë‹¤ìš©ë„ì ì´ì§€ë§Œ, ìš°ë¦¬ëŠ” ì´ë¥¼ í›¨ì”¬ ë” ì‚¬ìš©í•˜ê¸° ì‰¬ìš´ ë„êµ¬ë¡œ ì „í™˜í•˜ê³ , ë³µì¡í•œ ì»´í“¨í„° ì‚¬ì´ì–¸ìŠ¤ì™€ ë°ì´í„° ì‚¬ì´ì–¸ìŠ¤ ë…¸í•˜ìš°ë¥¼ ì²´ê³„í™”í•©ë‹ˆë‹¤.</td></tr>
<tr><td>So our go to market, as I said, we partnered with Arc Institute, because they had the data, they had the scientific expertise, we had the computer science expertise, and then we turned it into reusable recipes that is essentially codified in what is called BioNeMo. So every other researcher, can take and benefit from it. Josh Buchalter<br><br>Can I actually just ask now where you stand today? Are there any specific breakthroughs across AI healthcare space that you think will be potential watershed moments for even the biggest skeptics that we have today? Is it first AI generated drug to be approved by FDA? Like what does that look like to get the last of people on board with this?</td><td>ë”°ë¼ì„œ ìš°ë¦¬ì˜ ì‹œì¥ ì§„ì¶œ ì „ëµì€, ì œê°€ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, Arc Instituteì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºì—ˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ ë°ì´í„°ì™€ ê³¼í•™ì  ì „ë¬¸ì„±ì„ ë³´ìœ í•˜ê³  ìˆì—ˆê³ , ìš°ë¦¬ëŠ” ì»´í“¨í„° ì‚¬ì´ì–¸ìŠ¤ ì „ë¬¸ì„±ì„ ê°€ì§€ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë¥¼ BioNeMoë¼ê³  ë¶ˆë¦¬ëŠ” ì‹œìŠ¤í…œì— ì²´ê³„í™”ëœ ì¬ì‚¬ìš© ê°€ëŠ¥í•œ ë ˆì‹œí”¼ë¡œ ì „í™˜í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‹¤ë¥¸ ëª¨ë“  ì—°êµ¬ìë“¤ì´ ì´ë¥¼ í™œìš©í•˜ê³  í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>Josh Buchalter<br><br>ì§€ê¸ˆ í˜„ì¬ ìƒí™©ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦´ ìˆ˜ ìˆì„ê¹Œìš”? AI í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ì—ì„œ í˜„ì¬ ê°€ì¥ í° íšŒì˜ë¡ ìë“¤ì—ê²Œë„ ì ì¬ì ì¸ ì „í™˜ì ì´ ë  ìˆ˜ ìˆëŠ” êµ¬ì²´ì ì¸ ëŒíŒŒêµ¬ê°€ ìˆë‹¤ê³  ìƒê°í•˜ì‹œë‚˜ìš”? FDAê°€ ìŠ¹ì¸í•œ ìµœì´ˆì˜ AI ìƒì„± ì‹ ì•½ì´ ê·¸ëŸ° ê²ƒì¼ê¹Œìš”? ë§ˆì§€ë§‰ ë‚¨ì€ ì‚¬ëŒë“¤ê¹Œì§€ ë™ì°¸ì‹œí‚¤ë ¤ë©´ ì–´ë–¤ ëª¨ìŠµì´ì–´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Kimberly Powell<br><br>Yes. I absolutely do think that, it will be a watershed moment when one of those drugs gets through. It's not that, there isn't a huge amount of activity going on using AI for, for drug discovery, but it is the case that it's hard for investors to stay in it for a bit of this, this long haul and see that AI is actually that R&D productivity is not this AI found me a new drug. It's all about the process of doing R&D discovery in a much more efficient way, but that's not as sexy to invest in. And so I do believe that there are several late stage AI discovered drugs now that when that happens, I think it will be a huge wake up call.</td><td>í‚´ë²Œë¦¬ íŒŒì›”<br><br>ë„¤, ì €ëŠ” ê·¸ëŸ° ì•½ë¬¼ ì¤‘ í•˜ë‚˜ê°€ ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´ ë¶„ëª…íˆ ë¶„ìˆ˜ë ¹ì´ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹ ì•½ ê°œë°œì— AIë¥¼ í™œìš©í•˜ëŠ” ì—„ì²­ë‚œ í™œë™ì´ ì§„í–‰ë˜ê³  ìˆì§€ ì•Šë‹¤ëŠ” ê²ƒì€ ì•„ë‹ˆì§€ë§Œ, íˆ¬ììë“¤ì´ ì´ëŸ° ì¥ê¸°ì ì¸ ê³¼ì •ì— ê³„ì† ì°¸ì—¬í•˜ë©´ì„œ AIê°€ ì‹¤ì œë¡œ R&D ìƒì‚°ì„±ì„ ë†’ì¸ë‹¤ëŠ” ê²ƒì„ í™•ì¸í•˜ê¸°ëŠ” ì–´ë ¤ìš´ ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ì´ëŠ” 'AIê°€ ìƒˆë¡œìš´ ì•½ë¬¼ì„ ì°¾ì•„ì¤¬ë‹¤'ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, R&D ë°œê²¬ ê³¼ì •ì„ í›¨ì”¬ ë” íš¨ìœ¨ì ì¸ ë°©ì‹ìœ¼ë¡œ ìˆ˜í–‰í•˜ëŠ” ê²ƒì— ê´€í•œ ê²ƒì¸ë°, ì´ëŠ” íˆ¬ìí•˜ê¸°ì— ê·¸ë‹¤ì§€ ë§¤ë ¥ì ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì €ëŠ” í˜„ì¬ ì—¬ëŸ¬ í›„ê¸° ë‹¨ê³„ì˜ AI ë°œê²¬ ì•½ë¬¼ë“¤ì´ ìˆê³ , ê·¸ê²ƒì´ ì‹¤í˜„ë  ë•Œ ì—„ì²­ë‚œ ê°ì„±ì˜ ê³„ê¸°ê°€ ë  ê²ƒì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I kind of akin it to the Tesla Motors moment in the automotive industry where it's going to be then a foregone conclusion we have to go electric. It's a foregone conclusion we've got to have AI in the loop in everything that we're doing. So I would say, you know, a hefty part of the industry is definitely there's, there's the top that is doing AI in the loop. There is, you know, the next generation that is thinking about doing it. If that were to happen, it would just be everybody's going to see it as the only way forward because it truly is the, the only way forward. So I think that is going to be a fantastic watershed moment.</td><td>ì €ëŠ” ì´ê²ƒì„ ìë™ì°¨ ì‚°ì—…ì—ì„œì˜ í…ŒìŠ¬ë¼ ëª¨í„°ìŠ¤ ìˆœê°„ê³¼ ë¹„ìŠ·í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì „ê¸°ì°¨ë¡œ ê°€ì•¼ í•œë‹¤ëŠ” ê²ƒì´ ê¸°ì •ì‚¬ì‹¤ì´ ëœ ê²ƒì²˜ëŸ¼ ë§ì´ì£ . ìš°ë¦¬ê°€ í•˜ëŠ” ëª¨ë“  ì¼ì— AIë¥¼ ë£¨í”„ì— í¬í•¨ì‹œì¼œì•¼ í•œë‹¤ëŠ” ê²ƒì´ ê¸°ì •ì‚¬ì‹¤ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì—…ê³„ì˜ ìƒë‹¹ ë¶€ë¶„ì´ í™•ì‹¤íˆ AI ì¸ ë” ë£¨í”„ë¥¼ ì‹¤í–‰í•˜ê³  ìˆëŠ” ìµœìƒìœ„ ê·¸ë£¹ì´ ìˆê³ , ì´ë¥¼ ê³ ë ¤í•˜ê³  ìˆëŠ” ì°¨ì„¸ëŒ€ ê·¸ë£¹ì´ ìˆë‹¤ê³  ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë§Œì•½ ê·¸ëŸ° ì¼ì´ ì¼ì–´ë‚œë‹¤ë©´, ëª¨ë“  ì‚¬ëŒë“¤ì´ ì´ê²ƒì„ ìœ ì¼í•œ ì•ìœ¼ë¡œ ë‚˜ì•„ê°ˆ ê¸¸ë¡œ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ê²ƒì´ ì§„ì •ìœ¼ë¡œ ìœ ì¼í•œ ì•ìœ¼ë¡œ ë‚˜ì•„ê°ˆ ê¸¸ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ í™˜ìƒì ì¸ ë¶„ìˆ˜ë ¹ì´ ë˜ëŠ” ìˆœê°„ì´ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Brendan Smith<br><br>I guess just really quickly before I kick it back to Josh. Are there any important considerations from a regulatory perspective that investors should bear in mind as we try to understand kind of the market potential for AI within health care? Obviously, it's a moving target daily at this point, but, where things are today, anything that we should really be aware of? Kimberly Powell<br><br>I don't think that there's anything that has changed substantially. I do think that the regulatory, the market industry, excuse me, they're really trying hard to keep up in it. I hope we all feel a bit of onus in trying to educate them because, it's really crazy.</td><td>**ë¸Œë Œë“  ìŠ¤ë¯¸ìŠ¤**<br><br>ì¡°ì‹œì—ê²Œ ë‹¤ì‹œ ë„˜ê¸°ê¸° ì „ì— ê°„ë‹¨íˆ ì§ˆë¬¸ í•˜ë‚˜ë§Œ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í—¬ìŠ¤ì¼€ì–´ ë‚´ AIì˜ ì‹œì¥ ì ì¬ë ¥ì„ ì´í•´í•˜ë ¤ê³  í•  ë•Œ íˆ¬ììë“¤ì´ ì—¼ë‘ì— ë‘ì–´ì•¼ í•  ê·œì œ ê´€ì ì—ì„œì˜ ì¤‘ìš”í•œ ê³ ë ¤ì‚¬í•­ì´ ìˆì„ê¹Œìš”? ë¶„ëª…íˆ í˜„ì¬ ì‹œì ì—ì„œëŠ” ë§¤ì¼ ë³€í™”í•˜ëŠ” ìƒí™©ì´ì§€ë§Œ, ì˜¤ëŠ˜ í˜„ì¬ ìƒí™©ì—ì„œ ìš°ë¦¬ê°€ ì •ë§ ì•Œì•„ë‘ì–´ì•¼ í•  ê²ƒì´ ìˆë‚˜ìš”?<br><br>**í‚´ë²Œë¦¬ íŒŒì›”**<br><br>ì‹¤ì§ˆì ìœ¼ë¡œ í¬ê²Œ ë³€í™”í•œ ê²ƒì€ ì—†ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·œì œ ë‹¹êµ­, ì‹œì¥ ì—…ê³„ì—ì„œ, ì£„ì†¡í•©ë‹ˆë‹¤, ê·¸ë“¤ì´ ì •ë§ ë”°ë¼ì¡ìœ¼ë ¤ê³  ì—´ì‹¬íˆ ë…¸ë ¥í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ ëª¨ë‘ê°€ ê·¸ë“¤ì„ êµìœ¡í•˜ëŠ” ë° ì–´ëŠ ì •ë„ ì±…ì„ê°ì„ ëŠê¼ˆìœ¼ë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. ì •ë§ ë¯¸ì¹œ ìƒí™©ì´ê±°ë“ ìš”.</td></tr>
<tr><td>Even in medical imaging, ADOC is one of our great partners. They've created now an imaging foundation model, and they were able to get an FDA approved algorithm that is on the basis of that foundation model approved within months. This is good. This is a good sign. But of course, we don't want to do things that are unsafe either. Just like in the car industry, for example, the Rand Association declared you've got to drive a billion miles before you could ever be considered safe to drive autonomously, right? And if you did the math on that, the current fleet of instrumented cars, it would take a decade or more to be able to drive that amount of miles.</td><td>ì˜ë£Œ ì˜ìƒ ë¶„ì•¼ì—ì„œë„ ADOCì€ ì €í¬ì˜ í›Œë¥­í•œ íŒŒíŠ¸ë„ˆ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ê·¸ë“¤ì€ ì´ì œ ì˜ìƒ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ ê°œë°œí–ˆê³ , í•´ë‹¹ íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ ê¸°ë°˜ìœ¼ë¡œ í•œ FDA ìŠ¹ì¸ ì•Œê³ ë¦¬ì¦˜ì„ ëª‡ ë‹¬ ë§Œì— ìŠ¹ì¸ë°›ì„ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¢‹ì€ ì†Œì‹ì…ë‹ˆë‹¤. ì¢‹ì€ ì‹ í˜¸ì£ . í•˜ì§€ë§Œ ë¬¼ë¡  ì €í¬ëŠ” ì•ˆì „í•˜ì§€ ì•Šì€ ì¼ë“¤ì„ í•˜ê³  ì‹¶ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ ìë™ì°¨ ì—…ê³„ì—ì„œì²˜ëŸ¼, ëœë“œ í˜‘íšŒ(Rand Association)ëŠ” ììœ¨ì£¼í–‰ì´ ì•ˆì „í•˜ë‹¤ê³  ê°„ì£¼ë˜ê¸° ìœ„í•´ì„œëŠ” 10ì–µ ë§ˆì¼ì„ ì£¼í–‰í•´ì•¼ í•œë‹¤ê³  ì„ ì–¸í–ˆìŠµë‹ˆë‹¤, ê·¸ë ‡ì£ ? ê·¸ë¦¬ê³  ì´ë¥¼ ê³„ì‚°í•´ë³´ë©´, í˜„ì¬ì˜ ê³„ì¸¡ ì¥ë¹„ê°€ íƒ‘ì¬ëœ ì°¨ëŸ‰ í”Œë¦¿ìœ¼ë¡œëŠ” ê·¸ë§Œí¼ì˜ ê±°ë¦¬ë¥¼ ì£¼í–‰í•˜ëŠ” ë° 10ë…„ ì´ìƒì´ ê±¸ë¦´ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So how could technology potentially help you solve that? One of the things that we're leaning into, and this is going to be huge in the health care robotics space, is simulation environments. You can train the car to drive in a virtual world because we now have the ability to do it as such high fidelity and create the corner cases that you would probably never still see on those 1 billion miles traveled, and we can build that understanding into the model and make them much more robust.</td><td>ê·¸ë ‡ë‹¤ë©´ ê¸°ìˆ ì´ ì´ëŸ¬í•œ ë¬¸ì œë¥¼ í•´ê²°í•˜ëŠ” ë° ì–´ë–»ê²Œ ë„ì›€ì´ ë  ìˆ˜ ìˆì„ê¹Œìš”? ì €í¬ê°€ ì§‘ì¤‘í•˜ê³  ìˆëŠ” ë¶„ì•¼ ì¤‘ í•˜ë‚˜ì´ì í—¬ìŠ¤ì¼€ì–´ ë¡œë³´í‹±ìŠ¤ ì˜ì—­ì—ì„œ ë§¤ìš° ì¤‘ìš”í•œ ì—­í• ì„ í•  ê²ƒì€ ë°”ë¡œ ì‹œë®¬ë ˆì´ì…˜ í™˜ê²½ì…ë‹ˆë‹¤. ì´ì œ ë§¤ìš° ë†’ì€ ì •ë°€ë„ë¡œ ê°€ìƒ ì„¸ê³„ì—ì„œ ìë™ì°¨ ìš´ì „ì„ í›ˆë ¨ì‹œí‚¬ ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ê°–ì¶”ê²Œ ë˜ì—ˆê³ , 10ì–µ ë§ˆì¼ì„ ì£¼í–‰í•´ë„ ì—¬ì „íˆ ë§ˆì£¼ì¹˜ì§€ ëª»í•  ìˆ˜ ìˆëŠ” ê·¹í•œ ìƒí™©ë“¤ì„ ë§Œë“¤ì–´ë‚¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì´í•´ë¥¼ ëª¨ë¸ì— êµ¬ì¶•í•˜ì—¬ í›¨ì”¬ ë” ê²¬ê³ í•˜ê²Œ ë§Œë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And so we're going to have to help the FDA understand that there are technological advancements we can apply to show how much safer, in fact, by using computational methods, we're going to be making a lot of these AI algorithms or these medical systems going forward. So I think they're working really hard at it. I really respect the work that the FDA is doing. I think we can play a pivotal role in creating technologies, and then I think the conversation has to just be incredibly real. Nobody's seen this this pace of innovation in 100 years, right? I mean, we're all breathing from a fire hose. We're all waking up every single morning being like, what's new in AI today?</td><td>ë”°ë¼ì„œ ìš°ë¦¬ëŠ” FDAê°€ ê³„ì‚°ì  ë°©ë²•ë¡ ì„ í™œìš©í•¨ìœ¼ë¡œì¨ í–¥í›„ ì´ëŸ¬í•œ AI ì•Œê³ ë¦¬ì¦˜ì´ë‚˜ ì˜ë£Œ ì‹œìŠ¤í…œë“¤ì„ ì‹¤ì œë¡œ ì–¼ë§ˆë‚˜ ë” ì•ˆì „í•˜ê²Œ ë§Œë“¤ ìˆ˜ ìˆëŠ”ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ê¸°ìˆ ì  ì§„ë³´ë¥¼ ì ìš©í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ì´í•´í•  ìˆ˜ ìˆë„ë¡ ë„ì™€ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €ëŠ” ê·¸ë“¤ì´ ì •ë§ ì—´ì‹¬íˆ ë…¸ë ¥í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì €ëŠ” FDAê°€ í•˜ê³  ìˆëŠ” ì‘ì—…ì„ ì •ë§ ì¡´ê²½í•©ë‹ˆë‹¤. ìš°ë¦¬ê°€ ê¸°ìˆ ì„ ì°½ì¡°í•˜ëŠ” ë° ìˆì–´ ì¤‘ì¶”ì ì¸ ì—­í• ì„ í•  ìˆ˜ ìˆë‹¤ê³  ìƒê°í•˜ë©°, ê·¸ëŸ° ë‹¤ìŒ ëŒ€í™”ëŠ” ì •ë§ í˜„ì‹¤ì ì´ì–´ì•¼ í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì§€ë‚œ 100ë…„ ë™ì•ˆ ì•„ë¬´ë„ ì´ëŸ° ì†ë„ì˜ í˜ì‹ ì„ ë³¸ ì ì´ ì—†ìŠµë‹ˆë‹¤, ê·¸ë ‡ì£ ? ì¦‰, ìš°ë¦¬ ëª¨ë‘ê°€ ì†Œë°©í˜¸ìŠ¤ì—ì„œ ë‚˜ì˜¤ëŠ” ë¬¼ì„ ë§ˆì‹œê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ìš°ë¦¬ ëª¨ë‘ê°€ ë§¤ì¼ ì•„ì¹¨ ì¼ì–´ë‚˜ì„œ 'ì˜¤ëŠ˜ AIì—ì„œ ìƒˆë¡œìš´ ê²ƒì€ ë¬´ì—‡ì¸ê°€?'ë¼ê³  ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So, try doing that in a regulated industry and it's something that requires the entire industry to work on. Brendan Smith<br><br>On the topic of hurdles, do you feel like the health care industry is ready for all the innovation you're driving? And ask for two reasons. One, and at least from the outside looking in, is not necessarily the first one to adopt new technology usually, my dad still uses a fax machine, he's a physician. And then also from a cost standpoint, do you feel like we're at the point where cost is no longer prohibitive? Obviously, it's going to continue to move forward, but how do your customers think about where they are in the cost curve when they're adopting AI?</td><td>ë”°ë¼ì„œ ê·œì œ ì‚°ì—…ì—ì„œ ì´ë¥¼ ì‹œë„í•´ë³´ë©´, ì´ëŠ” ì „ì²´ ì‚°ì—…ì´ í•¨ê»˜ ë…¸ë ¥í•´ì•¼ í•˜ëŠ” ì¼ì…ë‹ˆë‹¤. <br><br>ë¸Œë Œë˜ ìŠ¤ë¯¸ìŠ¤<br><br>ì¥ì• ë¬¼ ì£¼ì œì™€ ê´€ë ¨í•´ì„œ, ì˜ë£Œ ì‚°ì—…ì´ ê·€í•˜ê°€ ì¶”ì§„í•˜ê³  ìˆëŠ” ëª¨ë“  í˜ì‹ ì„ ë°›ì•„ë“¤ì¼ ì¤€ë¹„ê°€ ë˜ì–´ ìˆë‹¤ê³  ìƒê°í•˜ì‹­ë‹ˆê¹Œ? ë‘ ê°€ì§€ ì´ìœ ë¡œ ë¬»ê² ìŠµë‹ˆë‹¤. ì²«ì§¸, ì ì–´ë„ ì™¸ë¶€ì—ì„œ ë³¼ ë•Œ ì˜ë£Œì—…ê³„ëŠ” ì¼ë°˜ì ìœ¼ë¡œ ìƒˆë¡œìš´ ê¸°ìˆ ì„ ê°€ì¥ ë¨¼ì € ë„ì…í•˜ëŠ” ì—…ê³„ê°€ ì•„ë‹™ë‹ˆë‹¤. ì œ ì•„ë²„ì§€ëŠ” ì˜ì‚¬ì¸ë° ì•„ì§ë„ íŒ©ìŠ¤ë¥¼ ì‚¬ìš©í•˜ê³  ê³„ì‹­ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¹„ìš© ê´€ì ì—ì„œë„, ì´ì œ ë¹„ìš©ì´ ë” ì´ìƒ ê¸ˆì§€ì ì´ì§€ ì•Šì€ ì§€ì ì— ë„ë‹¬í–ˆë‹¤ê³  ìƒê°í•˜ì‹­ë‹ˆê¹Œ? ë¬¼ë¡  ê³„ì†í•´ì„œ ë°œì „í•  ê²ƒì´ì§€ë§Œ, ê³ ê°ë“¤ì´ AIë¥¼ ë„ì…í•  ë•Œ ë¹„ìš© ê³¡ì„ ì—ì„œ ìì‹ ë“¤ì´ ì–´ëŠ ìœ„ì¹˜ì— ìˆë‹¤ê³  ìƒê°í•˜ëŠ”ì§€ ì–´ë–»ê²Œ ë³´ì‹­ë‹ˆê¹Œ?</td></tr>
<tr><td>Kimberly Powell<br><br>Yes, this is a great question too. I mean, you're right, the cost is getting completely manageable now. In fact, our Blackwell architecture, we've improved inference cost by 200 times in just two years. That means the cost curve of technology is going like this. The cost curve of human is on the other extreme. And so I think that is starting to be understood. What I don't think people quite understand yet is, the total cost of ownership and actually the return on investment can be huge. I have this fantastic example of building an avatar, a digital human, with Deloitte for the Ottawa Hospital.</td><td>í‚´ë²Œë¦¬ íŒŒì›”<br><br>ë„¤, ì´ê²ƒë„ ì •ë§ ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²Œ ë§ìŠµë‹ˆë‹¤. ë¹„ìš©ì´ ì´ì œ ì™„ì „íˆ ê´€ë¦¬ ê°€ëŠ¥í•œ ìˆ˜ì¤€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì €í¬ ë¸”ë™ì›° ì•„í‚¤í…ì²˜ë¡œ ë‹¨ 2ë…„ ë§Œì— ì¶”ë¡  ë¹„ìš©ì„ 200ë°° ê°œì„ í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê¸°ìˆ ì˜ ë¹„ìš© ê³¡ì„ ì´ ì´ë ‡ê²Œ í•˜í–¥í•˜ê³  ìˆë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ë°˜ë©´ ì¸ê±´ë¹„ ê³¡ì„ ì€ ì •ë°˜ëŒ€ ë°©í–¥ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ì ì´ ì´í•´ë˜ê¸° ì‹œì‘í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì‚¬ëŒë“¤ì´ ì•„ì§ ì™„ì „íˆ ì´í•´í•˜ì§€ ëª»í•˜ê³  ìˆëŠ” ê²ƒì€ ì´ì†Œìœ ë¹„ìš©(TCO)ê³¼ ì‹¤ì œ íˆ¬ììˆ˜ìµë¥ (ROI)ì´ ì—„ì²­ë‚  ìˆ˜ ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì €ëŠ” ë”œë¡œì´íŠ¸ì™€ í•¨ê»˜ ì˜¤íƒ€ì™€ ë³‘ì›ì„ ìœ„í•´ ì•„ë°”íƒ€, ì¦‰ ë””ì§€í„¸ íœ´ë¨¼ì„ êµ¬ì¶•í•œ í™˜ìƒì ì¸ ì‚¬ë¡€ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And every time you're going in for a surgery, there's always what's called a preoperative appointment. These preoperative appointments can range from an hour or two, generally with a trained clinical healthcare staff member. And a good 50% of that conversation is non-clinical. Where do I park? When do I need to stop taking my meds? When do I not I need to stop eating? Can I exercise before all of those kind of things where imagine you had a digital agent that you could call up any time of day and ask as many questions as you wanted? They recognize that they do 80,000 surgeries a year. Think about that, 160,000 hours of time spent.</td><td>ìˆ˜ìˆ ì„ ë°›ì„ ë•Œë§ˆë‹¤ í•­ìƒ ìˆ˜ìˆ  ì „ ìƒë‹´ì´ë¼ëŠ” ê²ƒì´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìˆ˜ìˆ  ì „ ìƒë‹´ì€ ì¼ë°˜ì ìœ¼ë¡œ í›ˆë ¨ë°›ì€ ì„ìƒ ì˜ë£Œì§„ê³¼ í•¨ê»˜ 1-2ì‹œê°„ ì •ë„ ì†Œìš”ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ëŒ€í™”ì˜ 50% ì •ë„ëŠ” ë¹„ì„ìƒì ì¸ ë‚´ìš©ì…ë‹ˆë‹¤. ì–´ë””ì— ì£¼ì°¨í•´ì•¼ í•˜ë‚˜ìš”? ì–¸ì œ ì•½ ë³µìš©ì„ ì¤‘ë‹¨í•´ì•¼ í•˜ë‚˜ìš”? ì–¸ì œ ì‹ì‚¬ë¥¼ ì¤‘ë‹¨í•´ì•¼ í•˜ë‚˜ìš”? ìˆ˜ìˆ  ì „ì— ìš´ë™ì„ í•´ë„ ë˜ë‚˜ìš”? ì´ëŸ° ì¢…ë¥˜ì˜ ì§ˆë¬¸ë“¤ ë§ì…ë‹ˆë‹¤. í•˜ë£¨ ì¤‘ ì–¸ì œë“ ì§€ ì „í™”ë¥¼ ê±¸ì–´ì„œ ì›í•˜ëŠ” ë§Œí¼ ì§ˆë¬¸í•  ìˆ˜ ìˆëŠ” ë””ì§€í„¸ ì—ì´ì „íŠ¸ê°€ ìˆë‹¤ê³  ìƒìƒí•´ë³´ì„¸ìš”. ê·¸ë“¤ì€ ì—°ê°„ 8ë§Œ ê±´ì˜ ìˆ˜ìˆ ì„ ì‹œí–‰í•œë‹¤ëŠ” ê²ƒì„ ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒê°í•´ë³´ì„¸ìš”, 16ë§Œ ì‹œê°„ì´ ì†Œìš”ë˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Imagine being able to deploy a digital system to take on 80,000 of those hours. If you did the math on that, that's essentially like being able to hire another 40 nurses. So the economics are fantastic actually in that situation. And not only are the economics and return on investment fantastic for the hospital, which as we know here in North America our economics are extremely poor and declining. So we need all of that capture back. But the patient experience, they studied the patient experience, it was 100%. Think about it. As a patient, you have a lot of angst, you want to ask a lot of questions.</td><td>80,000ì‹œê°„ì˜ ì—…ë¬´ë¥¼ ì²˜ë¦¬í•  ìˆ˜ ìˆëŠ” ë””ì§€í„¸ ì‹œìŠ¤í…œì„ ë°°ì¹˜í•  ìˆ˜ ìˆë‹¤ê³  ìƒìƒí•´ë³´ì„¸ìš”. ê³„ì‚°í•´ë³´ë©´, ì´ëŠ” ë³¸ì§ˆì ìœ¼ë¡œ 40ëª…ì˜ ê°„í˜¸ì‚¬ë¥¼ ì¶”ê°€ë¡œ ê³ ìš©í•˜ëŠ” ê²ƒê³¼ ê°™ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ìƒí™©ì—ì„œ ê²½ì œì„±ì€ ì‹¤ì œë¡œ ë§¤ìš° ë›°ì–´ë‚©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë³‘ì›ì— ëŒ€í•œ ê²½ì œì„±ê³¼ íˆ¬ììˆ˜ìµë¥ ì´ ë›°ì–´ë‚  ë¿ë§Œ ì•„ë‹ˆë¼ - ì—¬ê¸° ë¶ë¯¸ì—ì„œ ìš°ë¦¬ì˜ ê²½ì œì„±ì€ ê·¹ë„ë¡œ ì—´ì•…í•˜ê³  ê³„ì† ì•…í™”ë˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ê·¸ ëª¨ë“  ê²ƒì„ ë˜ì°¾ì•„ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ í™˜ì ê²½í—˜ì„ ì—°êµ¬í•œ ê²°ê³¼, 100%ì˜€ìŠµë‹ˆë‹¤. ìƒê°í•´ë³´ì„¸ìš”. í™˜ìë¡œì„œ ë§ì€ ë¶ˆì•ˆê°ì„ ê°€ì§€ê³  ìˆê³ , ë§ì€ ì§ˆë¬¸ì„ í•˜ê³  ì‹¶ì–´í•©ë‹ˆë‹¤.</td></tr>
<tr><td>If you're doing it with a human who you know is short on time, you're not going to ask as many questions. And so the patient experience went way up as well. So there was a win-win situation here on deploying digital technology. So that's an example where I don't think we're doing a good job describing that return on investment in that TCO. That was very simple math and pretty mind-boggling math. When it comes to, let me use the second example you gave of dad and fax and the â€“ unfortunately our healthcare system was architected for billing and things that are not really in service of the patient from the get-go. So we have a system that's been really, really tricky to innovate with.</td><td>ì‹œê°„ì´ ë¶€ì¡±í•œ ì˜ë£Œì§„ê³¼ í•¨ê»˜ ì§„í–‰í•  ë•ŒëŠ” ë§ì€ ì§ˆë¬¸ì„ í•˜ì§€ ì•Šê²Œ ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ í™˜ì ê²½í—˜ë„ í¬ê²Œ í–¥ìƒë˜ì—ˆìŠµë‹ˆë‹¤. ë””ì§€í„¸ ê¸°ìˆ  ë„ì…ì—ì„œ ìœˆ-ìœˆ ìƒí™©ì´ ë§Œë“¤ì–´ì§„ ê²ƒì´ì£ . ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ íˆ¬ììˆ˜ìµë¥ (ROI)ê³¼ ì´ì†Œìœ ë¹„ìš©(TCO)ì„ ì œëŒ€ë¡œ ì„¤ëª…í•˜ì§€ ëª»í•˜ê³  ìˆë‹¤ê³  ìƒê°í•˜ëŠ” ì‚¬ë¡€ì…ë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° ê°„ë‹¨í•œ ê³„ì‚°ì´ì—ˆê³  ìƒë‹¹íˆ ë†€ë¼ìš´ ìˆ˜ì¹˜ì˜€ìŠµë‹ˆë‹¤. <br><br>ë‘ ë²ˆì§¸ë¡œ ë§ì”€í•˜ì‹  ì•„ë²„ì§€ì™€ íŒ©ìŠ¤ ì‚¬ë¡€ì— ëŒ€í•´ì„œëŠ” - ì•ˆíƒ€ê¹ê²Œë„ ìš°ë¦¬ ì˜ë£Œ ì‹œìŠ¤í…œì€ ì²˜ìŒë¶€í„° ì²­êµ¬ì—…ë¬´ì™€ ê°™ì´ ì‹¤ì œë¡œëŠ” í™˜ìë¥¼ ìœ„í•œ ê²ƒì´ ì•„ë‹Œ ëª©ì ìœ¼ë¡œ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” í˜ì‹ í•˜ê¸°ê°€ ì •ë§, ì •ë§ ê¹Œë‹¤ë¡œìš´ ì‹œìŠ¤í…œì„ ê°–ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>I believe that is not any longer. I believe that because of agentic AI and the way that it is architected, it can overlay on this system. Unlike introducing technology in the past. For example, what can agents do? They can connect, so they have the foundation model, but that wasn't enough. They can connect into an API. We did build that into the health systems where they can API in, get your personalized data, they can API in, into a tool that is maybe an antiquated scheduling system. And so they can kind of navigate autonomously over what is otherwise a antiquated and very complex and disaggregated healthcare system.</td><td>ì €ëŠ” ë” ì´ìƒ ê·¸ë ‡ì§€ ì•Šë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì—ì´ì „í‹± AIì™€ ê·¸ê²ƒì´ ì„¤ê³„ëœ ë°©ì‹ ë•Œë¬¸ì—, ì´ ì‹œìŠ¤í…œ ìœ„ì— ì˜¤ë²„ë ˆì´ë  ìˆ˜ ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ê³¼ê±°ì— ê¸°ìˆ ì„ ë„ì…í•˜ëŠ” ê²ƒê³¼ëŠ” ë‹¬ë¦¬ ë§ì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ì—ì´ì „íŠ¸ë“¤ì´ ë¬´ì—‡ì„ í•  ìˆ˜ ìˆì„ê¹Œìš”? ì—°ê²°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. íŒŒìš´ë°ì´ì…˜ ëª¨ë¸ì„ ê°€ì§€ê³  ìˆì§€ë§Œ, ê·¸ê²ƒë§Œìœ¼ë¡œëŠ” ì¶©ë¶„í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. APIì— ì—°ê²°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì‹¤ì œë¡œ í—¬ìŠ¤ì¼€ì–´ ì‹œìŠ¤í…œì— ì´ë¥¼ êµ¬ì¶•í–ˆëŠ”ë°, ê°œì¸í™”ëœ ë°ì´í„°ë¥¼ ì–»ê¸° ìœ„í•´ APIë¡œ ì ‘ì†í•  ìˆ˜ ìˆê³ , êµ¬ì‹ ìŠ¤ì¼€ì¤„ë§ ì‹œìŠ¤í…œê³¼ ê°™ì€ ë„êµ¬ì—ë„ APIë¡œ ì ‘ì†í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ë“¤ì€ êµ¬ì‹ì´ê³  ë§¤ìš° ë³µì¡í•˜ë©° ë¶„ì‚°ëœ í—¬ìŠ¤ì¼€ì–´ ì‹œìŠ¤í…œ ìœ„ì—ì„œ ììœ¨ì ìœ¼ë¡œ íƒìƒ‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And so we have a lot of friends in the room who are building agents on top of this data to create new patient experiences. Abridge [ph], I don't know if your dad gets to use Abridge, but this is a clinical documentation platform that is a phone that the clinician sets in your room with them, says do you mind if I record. And now has all the opportunity to focus on you and not the computer. It summarizes, it does all of the clinical summarization and has a way after the clinician checks it for whatever it needs to do for the minor correction and it goes right into the electronic health record. This system is giving clinicians back two to three hours a day. A day.</td><td>ê·¸ë˜ì„œ ì €í¬ëŠ” ì´ ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì—ì´ì „íŠ¸ë¥¼ êµ¬ì¶•í•˜ì—¬ ìƒˆë¡œìš´ í™˜ì ê²½í—˜ì„ ì°½ì¶œí•˜ê³  ìˆëŠ” ë§ì€ íŒŒíŠ¸ë„ˆë“¤ì´ ìˆìŠµë‹ˆë‹¤. Abridge[ph]ì˜ ê²½ìš°, ì•„ë²„ë‹˜ê»˜ì„œ Abridgeë¥¼ ì‚¬ìš©í•˜ì‹¤ ìˆ˜ ìˆëŠ”ì§€ëŠ” ëª¨ë¥´ê² ì§€ë§Œ, ì´ëŠ” ì„ìƒì˜ê°€ ì§„ë£Œì‹¤ì—ì„œ í™˜ìì™€ í•¨ê»˜ íœ´ëŒ€í°ì„ ë†“ê³  "ë…¹ìŒí•´ë„ ê´œì°®ìœ¼ì‹œê² ìŠµë‹ˆê¹Œ?"ë¼ê³  ë¬»ëŠ” ì„ìƒ ë¬¸ì„œí™” í”Œë«í¼ì…ë‹ˆë‹¤. ì´ì œ ì„ìƒì˜ëŠ” ì»´í“¨í„°ê°€ ì•„ë‹Œ í™˜ìì—ê²Œ ì˜¨ì „íˆ ì§‘ì¤‘í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°–ê²Œ ë©ë‹ˆë‹¤. ì´ ì‹œìŠ¤í…œì€ ìš”ì•½ì„ í•˜ê³ , ëª¨ë“  ì„ìƒ ìš”ì•½ì„ ìˆ˜í–‰í•˜ë©°, ì„ìƒì˜ê°€ í•„ìš”í•œ ì‚¬í•­ì„ í™•ì¸í•˜ê³  ì‚¬ì†Œí•œ ìˆ˜ì •ì„ ê±°ì¹œ í›„ ë°”ë¡œ ì „ìê±´ê°•ê¸°ë¡(EHR)ì— ì…ë ¥ë˜ëŠ” ë°©ì‹ì„ ì œê³µí•©ë‹ˆë‹¤. ì´ ì‹œìŠ¤í…œì€ ì„ìƒì˜ë“¤ì—ê²Œ í•˜ë£¨ì— 2-3ì‹œê°„ì„ ëŒë ¤ì£¼ê³  ìˆìŠµë‹ˆë‹¤. í•˜ë£¨ì— ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So this is, I think what we are right at the precipice of. And as I said, these systems are for hire. They're on demand. They don't require you to hire a system integrator and get a $3 billion budget to hire a digital preoperative appointment agent. You can essentially do it, do it on demand. And so I think that's that transition is going to be right here in front of us. And â€“ you can already feel it as a patient, because Abridge is in my doctor's office. Josh Buchalter<br><br>Well, unfortunately, the red light says, we're out of time. But, Kimberly, what you and your team are working on is important. It's inspiring and it's exciting. So thank you and good luck. And thank you.</td><td>ê·¸ë˜ì„œ ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì ˆë²½ ëì— ì„œ ìˆëŠ” ì§€ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì´ëŸ¬í•œ ì‹œìŠ¤í…œë“¤ì€ ê³ ìš© ê°€ëŠ¥í•œ ì„œë¹„ìŠ¤ì…ë‹ˆë‹¤. ì˜¨ë””ë§¨ë“œ ë°©ì‹ì´ì£ . ì‹œìŠ¤í…œ í†µí•©ì—…ì²´ë¥¼ ê³ ìš©í•˜ê³  ë””ì§€í„¸ ìˆ˜ìˆ  ì „ ì˜ˆì•½ ì—ì´ì „íŠ¸ë¥¼ ìœ„í•´ 30ì–µ ë‹¬ëŸ¬ ì˜ˆì‚°ì„ í™•ë³´í•  í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ë³¸ì§ˆì ìœ¼ë¡œ ì˜¨ë””ë§¨ë“œ ë°©ì‹ìœ¼ë¡œ ì‹¤í–‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ëŸ¬í•œ ì „í™˜ì´ ë°”ë¡œ ìš°ë¦¬ ì•ì— í¼ì³ì§ˆ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  - í™˜ìë¡œì„œë„ ì´ë¯¸ ì´ë¥¼ ëŠë‚„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. Abridgeê°€ ì œ ë‹´ë‹¹ ì˜ì‚¬ ì§„ë£Œì‹¤ì— ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>Josh Buchalter<br><br>ì•ˆíƒ€ê¹ê²Œë„ ë¹¨ê°„ë¶ˆì´ ì¼œì ¸ì„œ ì‹œê°„ì´ ë‹¤ ë˜ì—ˆë„¤ìš”. í•˜ì§€ë§Œ Kimberly, ë‹¹ì‹ ê³¼ ë‹¹ì‹  íŒ€ì´ ì‘ì—…í•˜ê³  ìˆëŠ” ê²ƒì€ ì¤‘ìš”í•˜ê³ , ì˜ê°ì„ ì£¼ë©°, í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤. ê°ì‚¬ë“œë¦¬ê³  í–‰ìš´ì„ ë¹•ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Thank you for joining us. Kimberly Powell<br><br>Thank you. Thank you for having us. Brendan Smith<br><br>Thank you, everyone.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. í‚´ë²Œë¦¬ íŒŒì›”<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ë¥¼ ì´ˆëŒ€í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ë¸Œë Œë˜ ìŠ¤ë¯¸ìŠ¤<br><br>ì—¬ëŸ¬ë¶„, ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">â€¢ NVIDIAì˜ í—¬ìŠ¤ì¼€ì–´ ì‚¬ì—…ì€ ë””ì§€í„¸ ìˆ˜ìˆ , ë””ì§€í„¸ ìƒë¬¼í•™, ë””ì§€í„¸ í—¬ìŠ¤ 3ê°œ ë¶„ì•¼ì— ì¤‘ì ì„ ë‘ê³  ìˆìœ¼ë©°, ì „ì²´ $10ì¡° ê·œëª¨ì˜ í—¬ìŠ¤ì¼€ì–´ ì‚°ì—… ì¤‘ ì•½ 30%($3ì¡°)ê°€ AI ì¸í”„ë¼ íˆ¬ì ê¸°íšŒë¡œ ì˜ˆìƒë¨<br><br>â€¢ BioNeMo í”Œë«í¼ì„ í†µí•´ ì œì•½/ë°”ì´ì˜¤ ê¸°ì—…ë“¤ì˜ R&D ìƒì‚°ì„±ì„ í¬ê²Œ í–¥ìƒì‹œí‚¤ê³  ìˆìŒ - ê¸°ì¡´ 3-5ë…„ ì†Œìš”ë˜ë˜ í”„ë¡œì„¸ìŠ¤ë¥¼ ìˆ˜ê°œì›”ë¡œ ë‹¨ì¶• ê°€ëŠ¥<br><br>â€¢ ìµœê·¼ ì¶œì‹œëœ Blackwell ì•„í‚¤í…ì²˜ëŠ” 2ë…„ ë§Œì— ì¶”ë¡  ë¹„ìš©ì„ 200ë°° ì ˆê°í–ˆìœ¼ë©°, ë””ì§€í„¸ ì˜ë£Œ ì„œë¹„ìŠ¤ì˜ TCO(ì´ì†Œìœ ë¹„ìš©) ëŒ€ë¹„ ROIê°€ ë§¤ìš° ë†’ì€ ê²ƒìœ¼ë¡œ ì…ì¦ë¨<br><br>â€¢ ê·œì œ ì¸¡ë©´ì—ì„œëŠ” FDAê°€ AI í˜ì‹  ì†ë„ë¥¼ ë”°ë¼ê°€ê¸° ìœ„í•´ ë…¸ë ¥ ì¤‘ì´ë©°, ì‹œë®¬ë ˆì´ì…˜ í™˜ê²½ ë“± ìƒˆë¡œìš´ ê²€ì¦ ë°©ì‹ ë„ì…ì´ í•„ìš”í•œ ìƒí™©<br><br>â€¢ ê²½ì˜ì§„ì€ AI ê¸°ë°˜ ì‹ ì•½ì´ FDA ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´ ì—…ê³„ì˜ ëŒ€ëŒ€ì ì¸ ì „í™˜ì ì´ ë  ê²ƒìœ¼ë¡œ ì „ë§í•˜ë©° ë§¤ìš° ë‚™ê´€ì ì¸ í†¤ì„ ë³´ì„</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Question-and-Answer Session</td><td>ì§ˆì˜ì‘ë‹µ ì„¸ì…˜</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">ì£„ì†¡í•˜ì§€ë§Œ ìš”ì•½í•  ì‹¤ì œ ì‹¤ì ë°œí‘œ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. Q&A ì„¸ì…˜ì´ë¼ê³ ë§Œ í‘œì‹œë˜ì–´ ìˆì–´ì„œ êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ë¶„ì„í•˜ê³  ìš”ì•½í•˜ê¸° ì–´ë µìŠµë‹ˆë‹¤. <br><br>ì‹¤ì œ ì‹¤ì ë°œí‘œ ë‚´ìš©ì„ ê³µìœ í•´ ì£¼ì‹œë©´:<br>- ì£¼ìš” ì¬ë¬´ì§€í‘œ<br>- ê°€ì´ë˜ìŠ¤ ì—…ë°ì´íŠ¸ <br>- ê²½ì˜ì§„ì˜ í†¤<br>- ì ì¬ì  ë¦¬ìŠ¤í¬ì™€ ê°•ì <br><br>ë“±ì„ ì¤‘ì‹¬ìœ¼ë¡œ 3-5ê°œì˜ í•µì‹¬ í¬ì¸íŠ¸ë¡œ ìš”ì•½í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</p>
    <hr style="margin:50px 0;">
    
</body></html>